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Introduction 
 
Aging is often viewed as an unalterable process of decline and loss associated with 
development of physical frailty and gradual loss in cognitive function towards the end of life. 
This view may, however, be too pessimistic. The perceived importance of increasing the 
number of healthy years with a better preservation of functional and mental capacity grows 
with the increasing number of older persons in our society. The fulfillment of this need 
requires the identification of modifiable factors related to aging and explaining differences 
between individuals. In this thesis, we adopted the definition of successful aging by Rowe and 
Kahn, which includes avoidance of disease and disability, maintenance of high physical and 
cognitive function, and sustained engagement in social and productive activities 1.  
 
Endocrine system changes occurring with aging in women 
 
In the fourth decade, prior to a decline in ovarian function, the function of the 
somatotrophic axis begins to decrease. This decrease in function is further accelerated in 
parallel with the subsequent decline in ovarian function 2. As a result, growth hormone 
secretion, as well as circulating IGF-I and IGFBP-3 levels, decrease significantly with 
advancing age.  
Concentrations of ACTH and TSH remain constant well into the ninth decade. The thyroid 
gland undergoes progressive fibrosis and concentrations of T3 decline by 25 to 40%, but most 
elderly persons still remain euthyroid.  
Pancreatic B cell function also undergoes degeneration such that by age 65 years, 50% of 
subjects have abnormal glucose tolerance tests, and manifest type 2 diabetes occurs in 14% of 
the population 3.  
The function of female endocrine reproductive system fully stops at a (currently) relatively 
early age.  
Menopause, defined as the permanent cessation of menstruation, occurs at a mean age of 
51 years in women, as a result of a genetically programmed loss of ovarian follicles further 
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affected by environmental influences 4-7. With transition into menopause, estradiol levels 
decline by ~80%, whereas estrone levels are relatively preserved. The latter reflects peripheral 
aromatization of adrenal and ovarian androgens. FSH levels increase more than those of 
luteinizing hormone (LH), presumably because of the loss of inhibin combined with estrogen 
feedback. Because of the increase in gonadotropin secretion, which stimulates steroidogenesis 
in ovarian hilar cells or luteinized stromal cells, the ovaries become primarily androgen-
producing glands. The postmenopausal ovary produces a larger percentage of testosterone 
(50%) than does the premenopausal ovary. Still, the overall rate of testosterone production 
falls in postmenopausal women 8,9, mostly because of a decline in the peripheral and adrenal 
production of testosterone from androstenedione 10. From 3 years after the postmenopausal 
decline, intra-individual endogenous sex steroid serum concentrations remain relatively stable 
11-14
. The principal source of estrogens in postmenopausal women is thus peripheral 
aromatization of androstenedione to estrone in adipose tissue and skin, which is subsequently 
reduced to estradiol in peripheral tissues. There are several extragonadal estrogen production 
sites, including adipose tissue, bone, various sites of the brain, and vascular endothelial and 
smooth muscle cells 15-18. Postmenopausal estrogen production is thus primarily affected by 
body weight and not by age.  
Dehydroepiandrosterone sulfate (DHEAS) levels decrease in both men and women with 
aging. Androstenedione is the most important androgen during the reproductive years, and 
concentrations declines from 5.5 nmol/L to 2.9 nmol/L in postmenopausal women. The 
postmenopausal ovary contributes only 20% to circulating androstenedione levels. 
Given the endocrine changes associated with aging, many symptoms in the aging female 
may be due to estrogen deficiency or diminished androgen or growth hormone secretion. 
Disorders that are definitely due to estrogen deprivation include vasomotor symptoms and 
urogenital atrophy19,20. Osteoporosis is thought to be due largely to estrogen deficiency, but 
this may be exacerbated by the relative decline in growth hormone levels. The same may be 
said for the hormone-related increase in the prevalence of atherosclerotic cardiovascular 
disease, changes in body composition, and psychosocial symptoms, including insomnia, 
fatigue, short-term memory changes, and possibly depression. Both DHEAS and growth 
hormone may impact on these phenomena as well 2,21-24. 
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Manifestations of menopause 
1- Short term manifestations  
In the initial menopausal fall of ovarian function with aging, estradiol levels may be quite 
variable with chaotic patterns and occasionally very high or very low levels, and abnormal 
LH pulsatile patterns.  This marked variability may lead to a range of symptoms during the 
perimenopausal years. Hot flashes, a self-limited centrally mediated thermoregulatory 
dysfunction, with excessive peripheral vasodilatation and increased digital and cutaneous 
blood flow and perspiration, occurs in 75 percent of women 25. They are associated with 
sleeping problems, fatigue, irritability, depression, difficulties with cognitive concentration, 
and other emotional and psychological symptoms 26. Epithelial and mucosal atrophy and 
decreased local blood flow, are the major causes of decreased vaginal lubrication and sexual 
function in menopausal women 27 and predispose to stress and urge urinary incontinence 28. In 
addition to mucosal atrophy, estrogen deficiency can increase vaginal pH and alter the vaginal 
flora, changes which may predispose to urinary tract infection 29. Decreased skin and bone 
collagen content, reversible with estrogen hormone therapy 30, may lead to increased aging 
and wrinkling of the skin. Increases in collagen matrix in the bone probably result in an 
increase in flexibility and strength, independent of bone mineral density. Compelling 
evidence, including data from randomized clinical trials, indicates that estrogen therapy is 
highly effective for controlling vasomotor and genitourinary symptoms. 
2- Long term morbidity related to estrogen deficiency 
 
a- Cardiovascular disease  
Cardiovascular disease (CVD) is the leading cause of death in women, responsible for 
more deaths each year than all other causes combined 31. CVD is unusual in premenopausal 
women, particularly in the absence of other risk factors 32. The incidence of myocardial 
infarction in women, although lower than in men, increases after menopause. Because, due to 
increased life expectancy, women will now spend more than a third of their lives in the 
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postmenopausal years, cardiovascular preventive measures are thus important. The rapid 
increase in cardiovascular risk after menopause provided a strong reason to suspect that 
cessation of endogenous estrogen production played an important role 33,34. Consequently, a 
logical view was that substitution of endogenous hormones by exogenous estrogens would 
reduce the increased rate of cardiovascular disease in women. A large body of observational 
evidence supported a protective effect of estrogen replacement therapy on CVD 35,36. 
Subsequent randomized trials could, however, not substantiate the cardiovascular preventive 
benefits of estrogen replacement therapy 37-39.  A number of explanations for this discrepancy 
between observational and experimental data have been put forward, but as a consequence the 
enthousiasm about the preventive potential of estrogen replacement has much faded in recent 
years 40. The biological plausibility of a protective role of estrogen on cardiovascular disease 
is supported by the fact that exogenous estrogen lowers plasma low-density lipoprotein (LDL) 
cholesterol and raises high-density lipoprotein (HDL) cholesterol levels by 10 to 15%. 
Administration of estrogen also favorably affects lipoprotein(a) levels, LDL oxidation, 
endothelial vascular function, and fibrinogen and plasminogen activator inhibitor-1. However, 
estrogen therapy also has unfavorable effects on other biomarkers of cardiovascular risk, it 
boosts triglyceride levels, promotes coagulation via factor VII, prothrombin fragments 1 and 
2, and fibrinopeptide A elevations, and raises levels of the inflammatory marker C-reactive 
protein. 
Apart from a putative role of falls in endogenous estrogens, there are other risk factors 
related to menopause that are candidates to affect cardiovascular disease risk 41. Around 
menopause many women show an increase in body weight. Obesity is an important coronary 
risk factor as demonstrated in the prospective cohort Nurses' Health Study 42. The increase in 
risk associated with obesity was independent of diabetes, although the two disorders may be 
closely linked in individual patients 43. Abdominal or central obesity (waist-hip ratio of above 
0.9) is a stronger risk factor than simple body mass index measurements 43,44. 
b- Cognitive function 
Because the elderly are the fastest-growing segment of the population, and cognitive 
decline is strongly related to aging, the prevalence of dementia will increase markedly in 
coming years.  Although dementia appears not to preferentially affect women, the possible 
role of estrogen decline in women has also fuelled an interest in a role of estrogen and 
postmenopausal hormone therapy in cognitive function and dementia.  There is ample 
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biological evidence to support a role for estrogens in cognitive function. Estrogen receptors 
have been identified throughout the brain, and appear particularly common in the basal 
forebrain. The latest is the major source of cholinergic innervation to the hippocampus and  
important for regulation of memory and learning. The hippocampus is the primary region of 
the brain mediating cognitive function. However, most observational studies have not found a 
significant effect of endogenous estrogen levels on cognition in women and results from 
studies with hormone therapy have not supported a protective effect of exogenous estrogens 
on cognitive functions 45-52. Studies which addressed the role of the remaining circulating 
postmenopausal estrogens in cognition were hampered by small sample sizes or incomplete 
adjustment for potential confounders 53-56. Two studies reported reduced declines in cognitive 
function at higher circulating estradiol levels 14,57. In contrast, however, a recent study 
reported that higher serum estradiol levels were associated with an increased risk of 
Alzheimer’s disease 58. Two studies examined the continuous association between plasma 
estrogen concentration and cognitive function. No relation between estradiol or estrone and 
cognition or cognitive decline over time could be found 57,59. However, in one study reduced 
cognitive decline (measured by MMSE score) was observed in those women with the highest 
levels of free estradiol and bioavailable estradiol (presumably representing estradiol available 
to the brain). The findings were, however, based on a very small number of women with 
evidence of cognitive impairment 57. More data are clearly needed to conclude with 
confidence whether or not circulating estrogens affect cognitive function. 
c- Osteoporosis  
The most common skeletal disorder, osteoporosis, is characterized by low bone mass and 
micro-architectural deterioration of bone tissue. This leads to bone fragility and increased 
fracture risk. It also leads to considerable morbidity, mortality, and marked health care 
expense. Nearly half of postmenopausal women from an unselected population showed low 
bone density (almost 40% had osteopenia, and 7% osteoporosis) 60. Osteoporosis in 
postmenopausal women is the end result of years of bone loss due to an imbalance between 
bone resorption and bone formation. Both increase after menopause, but resorption exceeds 
formation, resulting in so called high-turnover osteoporosis 61,62. Soon after the onset of 
menopause there is a rapid acceleration of bone loss, particularly in trabecular bone. 
Menopause-related bone loss lasts for about 10 years. After this time, the rate of bone loss 
decreases 63,64. The mechanism by which lack of estrogen leads to increased bone loss in 
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women is not fully understood. Both direct effects of circulating estrogens on osteoclast 
function and changes in the release of certain cytokines appear to contribute. Whatever the 
mechanism, estrogen replacement therapy is highly effective in reducing risk of osteoporosis 
and fractures in postmenopausal women 65. On estrogen replacement, bone turnover and 
resorption rates are reduced and  bone loss attenuated. More than 50 randomized trials have 
demonstrated that postmenopausal estrogen therapy, with or without a progestin, rapidly 
increases bone mineral density at the spine by 4 to 6% and at the hip by 2 to 3%, and 
maintains those increases during treatment 66. 
d- Changes in body mass and composition  
Menopause, by the combination of aging and declined ovarian hormone secretion, is 
associated with changes in body composition. Loss of skeletal mass, loss of lean body mass, 
and increase in abdominal and visceral fat tissue have been described. 67 In addition, GH 
reductions lead to reduced protein synthesis, decreased lean body and bone mass, and 
increased percent body fat 68. Aging related changes in DHEAS levels have also been 
associated with alterations in body composition. Understanding the age-associated changes 
differences in regional fat redistribution and the metabolic correlates and factors that can 
modify these changes, may point at strategies to improve body composition profiles in the 
middle-aged and the elderly. 
The effects of Gonadotropin Releasing Hormone (GnRH) agonists (drugs inhibiting 
pituitary gonadotropin secretion, thereby profoundly suppressing ovarian estrogen 
production) on body composition have been well documented in prospective studies in men: 
GnRH agonists significantly decrease lean body mass and increase fat mass, most of the fat 
accumulation is in the subcutaneous tissues 69-71. The decrease in lean body mass and increase 
in fat mass appear to be early effects with minimal cumulative changes in body composition 
beyond 18 months of treatment 72. Treatment-related changes in body composition are 
accompanied by important metabolic changes including reduced insulin sensitivity 73 and an 
increase in serum lipids and lipoproteins 71,74. Reduced testosterone levels in men are 
probably responsible for the loss of lean body mass, increased body fat, and decreased muscle 
strength 70-72,75-77. Similar effects have been found in studies among women 78-80. 
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Aim of the thesis 
 
The aim of this study in healthy postmenopausal women was to gain further insight into 
the associations between endogenous estrogens and long term manifestations of menopause: 
cardiovascular aging (approximated by arterial stiffness), cognitive function (approximated by 
a global test), bone mineral density, body composition, physical functions and quality of life. 
This insight may yield answers about the potential for hormonal substitution therapy or other 
interventions which may improve the quality of life of women at older age and postpone 
morbidity.  
 
In Chapter 2, a study on determinants of large artery stiffness measured using aortic pulse 
wave velocity is presented  (Chapter 2.1), followed by a study on the relations between 
circulating endogenous hormones and arterial stiffness (Chapter 2.2). Chapter 3 contains a 
study on the relations between endogenous estrogen and cognition. Chapter 4 focuses on the 
contribution of determinants of bone mineral density (fat mass, lean mass and endogenous 
hormones) at various locations. Body composition is studied in Chapter 5 by assessing the 
relationships between body composition, physical function and disability.  Chapter 6 
concerns relations between endogenous hormones, body composition and physical 
performance.  
Finally, body composition, functional and hormonal parameters and quality of life were 
studied in Chapter 7. 
In Chapter 8, the results described in this thesis are summarized, put in a broader 
perspective and views on further research are put forward. 
Chapter 9 provides a summary of this thesis in Dutch. 
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Abstract 
 
Objective : To investigate the degree and potential cardiovascular determinants of arterial stiffness, 
assessed by aortic pulse wave velocity (PWV) measurements, and to relate arterial stiffness to absolute 
10-12-year risks of stroke, coronary heart disease and death, as estimated by available risk functions, in 
postmenopausal women.  
Method : We performed a cross-sectional study among 385 postmenopausal women, aged 50-74 
years, sampled from the general population. Arterial stiffness was assessed non-invasively by 
measurement of aortic PWV using applanation tonometry. Information on health was obtained by 
medical history, registration of current medication, and physical examination. Height, weight, waist and 
hip circumferences, fasting glucose, total and high-density lipoprotein (HDL) cholesterol, triglycerides, 
resting blood pressure, and heart rate were measured. Three risk scores were used to estimate, for each 
individual, the absolute risk of stroke, coronary heart disease, and death within 10-12 years as a 
function of their cardiovascular risk factor profile. The relationship between PWV and these risk scores 
was subsequently determined.  
Results : Significant positive relationships with PWV were found for body mass index, fasting 
glucose, diabetes mellitus, and triglycerides in analyses adjusted for age, mean arterial blood pressure, 
and heart rate. Height and HDL cholesterol were inversely related to PWV. The risks of stroke, 
coronary heart disease, and death increased with increasing PWV in a linear graded manner. 
Conclusions : This cross-sectional study among postmenopausal women provides evidence that 
most of the established cardiovascular risk factors are determinants of aortic PWV. Increased PWV 
marks an increased risk of stroke, coronary heart disease, and death within 10-12 years. 
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Introduction 
 
Originally, increased arterial stiffness was considered to be intrinsic to the aging process of 
the artery [1]. However, it has since been demonstrated that factors such as insulin resistance, 
hypertension, atherosclerosis, and end-stage renal disease (ESRD) [2-9] contribute to the 
stiffening of the arterial tree. 
The clearest consequences of arterial stiffening of large arteries, in particular the aorta, are 
increased pulsatile blood pressure as a result of a greater systolic (SBP) and a lower diastolic 
(DBP) pressure, which leads to a increased left ventricular workload in combination with a 
reduced perfusion of the coronary arteries in diastole [10]. Recent population-based studies 
have emphasized the increasing interest in markers of arterial stiffness, measurable in a non-
invasive manner, each with it own characteristics: brachial pulse pressure, carotid 
distensibility, and aortic pulse wave velocity (PWV) [10,11]. 
There have been a number of studies indicating that increased incidences of cardiovascular 
disease are related to stiffer vessels [2-16]. The most prominent factor is age: with increasing 
age, arteries become stiffer, apparently in a similar manner for both men and women [17]. In 
addition, increased blood pressure and indicators of glucose intolerance are strongly related to 
increased arterial stiffness [18,19]. A number of studies have examined the relationship 
between arterial stiffness and the presence of atherosclerotic abnormalities elsewhere in the 
arterial tree [6-8]. An increased aortic PWV showed a linear graded relationship to carotid 
intima-media thickness, plaques in the carotid arteries, lower extremity arterial disease, and 
plaques in the abdominal aorta [8]. In a group of patients with hypertension, aortic PWV was 
positively related to the absolute risk of cardiovascular disease, as estimated by available risk 
functions [20]. 
Most of the evidence that relates arterial stiffness to risk factors and the presence of 
atherosclerosis and prevalent cardiovascular disease comes from studies performed in specific 
groups of patients. Information on these issues for postmenopausal women is very limited. 
Some available data stem from studies of the influence of oestrogen; menopause seems to be 
associated with stiffer vessels [21-23]. However, studies that evaluated whether hormonal 
therapy (HT) had a direct beneficial effect on arterial stiffness have yielded conflicting findings 
[24-26]. Nevertheless, studies of HT and endothelial function [27], and of HT and 
atherosclerosis [28] - both major determinants of arterial stiffness - showed positive results 
overall. 
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The aim of this study was to investigate the major determinants of aortic stiffness, measured 
by aortic PWV, in postmenopausal women. In addition, we related PWV to estimates of 
individual 10-12-year absolute risk of stroke, coronary heart disease, and death. Three risk 
scores were used to estimate the individual absolute risk of stroke, coronary heart disease, and 
death as a function of their cardiovascular risk factor profile [29-31]. 
 
Participants and methods 
 
Study population 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) [32]. 
In PROSPECT, a total of 17 395 healthy women presenting for breast cancer screening, who 
were aged 49-70 years and living in Utrecht and the surrounding area, were enrolled between 
1993 and 1997. Using the baseline data from PROSPECT, we selected women who had 
experienced a natural menopause between 8 to 30 years ago. In addition, criteria for inclusion 
in the study were that the woman should have an intact uterus and at least one intact ovary, and 
should not have used sex steroids after the reported date of last menstruation. These criteria 
were used because the primary objective of the present study was to elucidate the role of 
endogenous sex hormones on several markers of frailty. Of 1803 eligible women, 902 were 
invited to participate and 553 (61%) agreed to do so. 402 participants were finally included in 
the study. Women were considered sufficiently healthy to participate when they were 
physically and mentally able to visit the study centre without assistance. Each participant 
underwent all tests and assessments during two visits to the study centre. The study was 
approved by the Institutional Review Board of the University Medical Center Utrecht and 
written informed consent was obtained from all participants. Data collection took place 
between September 1999 and March 2000. 
 
Measurements 
 
Information on health was obtained by medical history, registration of current medication 
and physical examination. A standardized questionnaire on use of oestrogen, alcohol 
consumption, and smoking was obtained from all women. Individuals were categorized as 
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current smokers, former smokers, and those who had never smoked. For current and past 
smokers, the number of pack-years was calculated as the average number of packs of cigarettes 
smoked per day multiplied by the total years of smoking. Height, weight, and waist and hip 
circumferences were measured with the woman in a standing position wearing indoor clothes 
and no shoes. Body mass index (BMI) was calculated as the weight in kilograms divided by the 
square of the height in metres. 
 
Blood pressure and heart rate were measured during the first visit using an oscillometric-
automated device (Dinamap 8100, Critikon). Measurements were conducted before 1100 h 
after an overnight fast. After 5 min of rest, blood pressure was taken at the right brachial artery 
simultaneously with heart rate, twice with the participant lying down and three times with the 
participant in a standing position, with 1 min between each measurement. SBP and DBP were 
defined as the average of the two supine measurements. Mean arterial blood pressure (MAP) 
was calculated as DBP + [(SBP - DBP)/3]. Pulse pressure was defined as SBP minus DBP. 
Hypertension was defined as SBP at least 160 mmHg, DBP at least 95 mmHg, use of 
antihypertensive medication, or a combination thereof [33]. Isolated systolic hypertension was 
defined as SBP at least 160 mmHg and DBP 90 mmHg or less without medication. Fasting 
venous blood samples were obtained between 0800 and 1100 h. Total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglyceride, glucose and albumen were measured 
reflectometrically using commercial enzymatic kits with a Vitros 250 (dry chemistry; Johnson 
& Johnson, Rochester, Minnesota, USA). Glucose was measured by the glucose 
oxidase/peroxidase method. Total cholesterol was measured by adaptation of the cholesterol 
oxidase/peroxidase method (fixed time). Triglycerides were measured by the 
lipase/glycerolkinase/GPO/POD method (fixed time). HDL cholesterol was measured after 
precipitation with dextran sulphate/Mg2+. The low-density lipoprotein (LDL) cholesterol 
concentration was estimated using the Friedewald formula [34]. Hypercholesterolaemia was 
defined as a total cholesterol concentration of 6.5 mmol/l or more, or use of cholesterol-
decreasing drug treatment. Diabetes mellitus was defined as fasting serum glucose of 7.0 
mmol/l or more, or the use of oral glucose-decreasing drugs or insulin [35]. 
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The Sphygmocor system was used for non-invasive measurement of the stiffness of the 
aorta [36] (PWV system, PWV Medical, Sydney, Australia). After the woman had rested for 5-
10 min in the supine position, aortic PWV was measured by sequential recordings of the 
arterial pressure waveform at the carotid artery and the femoral artery, using a hand-held 
micromanometer-tipped probe on the skin at the site of maximal arterial pulsation. Gating the 
recordings at those two sites to the electrocardiogram (ECG) enabled PWV to be measured. 
Recordings were taken when a reproducible signal was obtained with high-amplitude excursion 
- usually 10 consecutive beats, to cover a complete ventilatory cycle. The wave transit time 
was calculated by the system software, using the R wave of a simultaneously recorded ECG as 
a reference frame. Distances from the carotid sampling site to the suprasternal notch and from 
the suprasternal notch to the femoral artery were measured using a compass [37]. The aortic 
PWV (m/s) was automatically calculated as the distance between the suprasternal notch and the 
femoral artery minus the distance between the carotid sampling site and the suprasternal notch, 
divided by the time interval between the systolic R wave and the femoral systolic up-stroke 
minus the time interval between the systolic R wave and the carotid systolic up-stroke. Aortic 
PWV was determined as the mean of at least three consecutive beats recorded during 10 s of 
data acquisition. All measurements were performed by the same observer (C.E.I.L.)  
 
We performed a reproducibility study among 27 participants, who underwent a second 
PWV measurement within 2 weeks after the first examination. The mean (SD) PWV was 9.55 
(2.36) m/s at the first visit and 9.56 (2.01) m/s at the second visit, with a mean difference of 
0.01 (1.0) m/s. The within-class correlation coefficient was 89.6%, indicating that 89.6% of the 
variance in the PWV measurements was attributable to differences between patients, whereas 
10.4% could be attributed to differences between visits (measurement error and intra-individual 
variability). 
 
Risk functions for stroke, coronary heart disease, and all-cause mortality.   
 
A risk function for an individual estimates the probability of the occurrence of an event 
within a certain time span as a function of the individual's level of the risk indicators. Risk 
functions are derived from analyses on data from longitudinal (cohort) studies, in which the 
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relative and independent contribution of certain risk factors in predicting the occurrence of the 
event are evaluated.  
The risk function for stroke was based on information from 10 years of follow-up of 
participants in the Framingham Heart Study, who were aged 55-84 years and initially free from 
stroke, at biannual examinations 9 and 14 [29]. A Cox proportional hazards model was used to 
estimate the contribution of cardiovascular risk factors to the occurrence of stroke. The report 
provides detailed information on how an individual's absolute 10-year risk of stroke may be 
estimated. For women, this is:  
 
Equation {1 - 0.9353exp[0.0699(age) + 0.0161(SBP) + 0.00026(HRXSBP) + 0.4404(CVD) + 0.8055(ECGLVH) + 
0.5219(smoking) + 1.1173(Atrial fibrillation) + 0.5604(diabetes) - 7.5766)]
,} 
 
where HRXSBP = 0 if systolic pressure 200 mmHg, else HRXSBP is HRX(SBP - 110)(200 
- SBP) and HRX = 1 when individual is receiving antihypertensive treatment; CVD, 
cardiovascular disease present; ECGLVH, left ventricular hypertrophy on ECG.  
The risk function predicting 10-year coronary heart disease risk was obtained from data of 
the Framingham Heart cohort aged 30-74 years and free from cardiovascular disease at 
baseline [30]. A logistic regression model was used for risk estimation. Risk indicators 
included in the final model were age, SBP, total : HDL cholesterol ratio, left ventricular 
hypertrophy (on ECG), smoking, and diabetes mellitus. In the report [30], an extensive and 
detailed description is given of how to arrive at an estimate of the absolute risk of coronary 
heart disease within 10 years for an individual, given a certain set of cardiovascular risk 
factors.  
The risk function to predict an individual's probability of dying within 11.5 years as a 
function of the levels of cardiovascular risk factors was obtained from findings in a follow-up 
study among 6057 individuals aged 20 years or over, conducted in the Netherlands [31]. A Cox 
proportional hazards model was used to identify the most relevant cardiovascular factors for 
death. For each individual, an absolute risk of dying within 11.5 years may be calculated. For 
women, this is: 
{1 - 0.99945exp[0.081(age) + 0.010*(SBP) + 0.001*(pulse rate) + 0.119(smoking) + 0.160(antihypertensive drugs) + 
0.700(diabetes mellitus) + 0.436(myocardial infarction) - 0.036(BMI)]}
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Data analysis 
 
Data on PWV were not available for 18 women, leaving results from 385 women for 
analysis. General characteristics of the study population were described by the mean and SD. 
The association between PWV measurements and cardiovascular risk factors was evaluated 
using linear regression analysis, and the associations are presented with the linear regression 
coefficient ([beta]) and its SE. As it is known from the literature that age, mean arterial blood 
pressure, and heart rate are major determinants of PWV, we adjusted for these factors when 
evaluating the association with other determinants using multiple linear regression. We 
evaluated whether the associations differed between women with an early menopause (1969-
1979) or a late menopause (1987-1989). Because all interaction terms had a P value > 0.40, no 
evidence for modification was found. Therefore, overall findings are reported. For each of the 
385 individuals, we calculated the absolute risk of stroke, coronary heart disease, and death, 
using the formulae described above. Then, we evaluated the association between these risk 
estimates and PWV using linear regression analyses. Statistical analyses were performed using 
SPSS for Windows (version 9.0). 
 
Results 
 
The general characteristics of the study participants are given in Table 1.  
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The 385 participants were aged 56-73 years. The PWV distribution is depicted in Figure 1, 
showing a mean (SD) PWV value of 9.2(2.2) m/s.  
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Fig. 1 Distribution of pulse wave velocity in a population of 385 postmenopausal women.  
 
Determinants of PWV 
The results of the analysis of risk factors and PWV are presented in Table 2. 
 
Increasing age, blood pressure (systolic, diastolic, pulse, and mean arterial), and heart rate 
were related to increased PWV. In analyses in which age, mean arterial blood pressure, and 
heart rate were taken into account, graded associations were found for BMI, weight, height, 
LDL cholesterol, HDL cholesterol, triglycerides, glucose, diabetes mellitus, insulin, and pack-
years of smoking. In a multivariate model, the main factors that remained independently 
related to an increased PWV were mean arterial pressure, pulse pressure, age, heart rate, the 
number of pack-years of cigarettes smoked, and HDL cholesterol (inverse relationship) (Table 
3). 
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PWV and absolute risk of disease 
 
The 10-year absolute risk of stroke increases gradually with increasing aortic PWV (Fig. 2). 
An increase in PWV of 1 m/s was associated with an increase in absolute risk of stroke of 0.9 
[95% confidence interval (CI) 0.7 to 1.1]. The risk of dying within 11.5 years by quintile of 
aortic PWV is shown in Figure 3. An increase in PWV of 1 m/s was associated with increase in 
absolute risk of death of 2.2% (95% CI 1.8 to 2.6). The risk of coronary heart disease within 10 
years by quintile of aortic PWV is given in Figure 4. A graded positive association was found, 
with an increase in PWV of 1 m/s associated with a 1.4% (95% CI 0.9 to 1.9) increased risk of 
coronary heart disease.  
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Discussion 
 
This cross-sectional study provides evidence that, among postmenopausal women, increased 
arterial stiffness assessed non-invasively by PWV is significantly and positively associated 
with age, mean arterial pressure, pulse pressure, heart rate, and pack-years of cigarette 
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smoking. Height and HDL cholesterol were found to be inversely related to PWV. In addition, 
this study suggests that PWV is a clear marker of an increased absolute risk of stroke, coronary 
heart disease, and death within 10-12 years.  
Before these results can be accepted, some aspects of this study need to be considered. The 
measurement of aortic PWV - distance divided by time – allows only an estimate of the actual 
distance travelled by the pulse, and not the exact distance. The latter can be assessed only with 
invasive procedures. We tried to approach the true distance by subtracting the distance between 
the suprasternal notch and the carotid location from the distance between the suprasternal notch 
and the femoral sampling site, because the pulse travels in the opposite direction [10]. This 
might underestimate PWV, because arteries become longer and more tortuous with age. 
However, we consider the error in the distance to be relatively small and therefore not to affect 
our results seriously. If anything, it might bias our findings towards an underestimation of the 
associations. 
Our findings confirm those from other studies indicating that age, blood pressure, and heart 
rate are related to increased aortic stiffness. The age-related increase in PWV may be explained 
by physiological degeneration of elastic fibres, with parallel increases in collagen and 
mucopolysaccharides within the media, and accumulation of vascular smooth muscle cells in 
the arterial wall. Those changes are known to be exacerbated by hypertension, arterial 
degeneration, and cardiac and arterial disease, and are most marked in central arteries such as 
the aorta [10,16,20,38,39]. The relationship to heart rate may be partly the result of an 
adrenergic influence on the aortic wall, increasing the smooth muscle tone and leading to 
increased stiffness of the arterial wall [40]. However, it has been shown that, in elastic arteries, 
the stiffening effect of tachycardia is exerted independently of sympathetic modulation of the 
vessel wall properties and that, in muscular arteries, removal of sympathetic influences 
unmasks the stiffening effect of tachycardia [41-43]. In addition to these three factors, an 
inverse relationship between body height and PWV has been reported in other studies. Short 
stature is associated with early systolic arrival of reflected waves, which stiffens the aorta and 
increases the pulsatile effort of the left ventricle [8,44,45]. Finally, in our analyses, indicators 
of the insulin resistance syndrome appeared to be related to an increased aortic stiffness - an 
observation in agreement with the findings of other studies [2,3]. Recently, attention has been 
focused on the effects of HT in directly affecting vascular characteristics such as endothelial 
function and atherosclerosis, in an attempt to reduce the risk of future cardiovascular disease 
[27,28]. By influencing endothelial function and atherosclerosis, HT may also affect arterial 
stiffness, as these are the two main determinants of arterial stiffness. At present, however, the 
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advantages and disadvantages of HT in reducing cardiovascular disease events in primary and 
secondary prevention continue to be strongly debated [27,46,47]. Our results points towards 
traditional risk factors as the main determinants of arterial stiffness at menopause, and provide 
a rationale for developing treatment strategies. 
The present analyses suggest that an increased PWV is associated with an increased risk of 
stroke, coronary heart disease, and all-cause mortality, as estimated by available risk functions. 
This finding of an association of increased PWV and absolute risk of cardiovascular disease 
estimated using risk functions agrees with findings from a similar study performed in 
hypertensive individuals [16]. Although both studies suggest that PWV is a clear marker of 
risk, they had a cross-sectional design, which does not allow inferences as to cause and 
consequence. Furthermore, the contribution of measurement of arterial stiffness in predicting 
future disease, relative to that of other cardiovascular risk factors, cannot be determined using 
studies of that design, but needs to be addressed in a prospective follow-up study. 
Direct evidence of the predictive value of measurements of arterial stiffness comes from a 
small number of studies, mostly among patients with ESRD. In a cohort of 241 patients with 
ESRD after a mean follow-up of 72 months, increased aortic PWV was associated with all-
cause and cardiovascular mortality [15,48,49]. The importance of the prognostic value of aortic 
PWV measurements in patients with ESRD was further demonstrated in a cohort of 150 such 
patients [48]. In a recent study among 1980 patients with essential hypertension, who were 
followed for an average of 4.2 years [49], an increase in PWV of 5 m/s was associated with an 
increased risk of death of 2.14 (95% CI 1.71 to 2.67) and an increased risk of cardiovascular 
mortality of 2.35 (95% CI 1.76 to 3.14). These relationships remained statistically significant 
after adjustments for age, previous symptomatic cardiovascular disease, and diabetes mellitus. 
Information on the relation of arterial stiffness and risk of cardiovascular disease among other 
high-risk groups or for the population at large is still lacking. The present study had a cross-
sectional design and thus does not allow conclusions to be drawn that are based on longitudinal 
data. However, we believe that our conclusion that 'PWV is a marker of risk' may be 
substantiated by two observations. First, in our study, an increased PWV was related to 
increased risk factors. Thus, if an increased PWV is found in a patient, this patient is likely to 
have increased risk factors and therefore is at increased risk of cardiovascular disease. This 
reasoning has been further substantiated by several follow-up studies relating an increased 
PWV to incident cardiovascular disease events. Second, in our study an increased PWV related 
to increased absolute risk of cardiovascular disease as assessed using the Framingham Heart 
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Study risk function. This observation also indicates that, when an increased PWV is found in a 
patient, this patient is likely to be at increased risk of future cardiovascular disease events. 
In conclusion, this cross-sectional study among postmenopausal women provides evidence 
that PWV of the aorta is associated with increases in most of the established cardiovascular 
risk factors. In addition, it supports the importance of assessment of arterial stiffness as a 
marker for cardiovascular disease risk that may be of use as an endpoint in observational and 
intervention studies. 
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 2.2 Arterial stiffness is not related to 
remaining endogenous hormone in healthy 
postmenopausal women 
 
 
 
 
Abstract 
 
Objective: There is ample data to suggest that endogenous estrogen exposure may protect against 
cardiovascular disease. Consequently, CVD risk is expected to increase with decreasing estradiol 
levels. The aim of this study was to investigate whether postmenopausal levels of sex hormones, sex 
hormone-binding globulin, and a number of other hormones which have been implicated in the aging 
process are associated with arterial stiffness, a proxy for cardiovascular disease risk, among healthy 
postmenopausal women. 
Method: We performed a cross-sectional study among 384 women aged 56-73 years, 8 to 30 
years postmenopausal not using exogenous hormones. Serum concentration of estradiol, estrone, and 
sex hormone-binding globulin (SHBG), testosterone, cortisol, androstenedione, DHEA and DHEAS, 
Insulin-like Growth Factor (IGF-1), its binding proteins (IGFBP –1 and –3) and insulin, were all 
determined by radio immuno assay. Height, weight, waist and hip circumferences, fasting glucose, 
total and HDL cholesterol, triglycerides, resting blood pressure and heart rate were measured. Arterial 
stiffness was non-invasively assessed by pulse wave velocity measurement of the aorta using 
applanation tonometry. 
Results: Circulating estradiol, estrone and SHBG levels were not related to pulse wave velocity. 
None of the other circulating hormone levels measured was associated to pulse wave velocity either. 
Conclusions: This cross-sectional study does not support the hypothesis that lower circulating 
estrogens levels are associated with stiffer arteries in healthy women 8 to 30 years postmenopausal.  
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Introduction 
 
Cardiovascular disease is currently the most common cause of death and a significant 
cause of disability among postmenopausal women in Western societies. Because the aging of 
the population in most Western countries is more pronounced in women than in men, 
cardiovascular disease has become a major health issue in women. Several lines of evidence 
have suggested that endogenous estrogens may protect against atherosclerosis and subsequent 
cardiovascular disease (CVD). Early cessation of endogenous estrogen production, as occurs 
in early menopause or after surgical ovariectomy, has been shown to increase CVD risk 1-3.  
Since atherosclerosis and arterial stiffness are present long before the development of 
symptomatic coronary heart disease, pulse wave velocity measurements might be useful to 
detect cardiovascular risk at an early stage. A stiffer aorta has been associated with 
unfavorable levels of cardiovascular risk factors, with presence of coronary heart disease, 
atherosclerosis elsewhere and future CVD risk 4-6. As such, aortic stiffness is an appropriate 
marker of cardiovascular risk. This simple, reliable, non-invasive method provides a way to 
study vascular characteristics in populations at large. 
Previous studies do not support associations between postmenopausal remaining 
circulating estrogens levels and symptomatic cardiovascular disease 7-9. In an attempt to 
provide further insight into the relationships between postmenopausal sex steroids and CVD, 
we have examined the associations between remaining estrogen levels measured with new 
more sensitive methods and aorta stiffness measured by aortic pulse wave velocity. In 
addition, associations between a number of other hormones that have been implicated in the 
aging process and aorta stiffness were studied. 
 
Subject and methods 
 
Study population and measurements 
 
We used for this study the same population and measurements as previously described 10. 
See chapter 2.1. 
 
42 
Chapter 2 
 
Complementary biochemical assessments 
 
Serum concentrations of estradiol (E2, nmol/l), estrone (E1, nmol/l), DHEA (nmol/l) and 
DHEAS (µmol/l) and total testosterone (T, nmol/l) were estimated using ultra-sensitive 
double-antibody radioimmunoassay commercial kits purchased from Diagnostic Systems 
Laboratories (Webster, TX, USA). Sex hormone binding globulin (SHBG, nmol/l) was 
measured using a chemoluminescence-based immunometric assay on the Immulite 2000 
system (Diagnostic Products Corporation, Los Angeles, CA, USA). Total IGF-1 was 
determined by a IGFBP-blocked RIA in the presence of large excess of IGF-II as described 
(Blum WF, 1994 Growth regul. 4:11-9). IGFBP-1 and IGFBP-3 were measured with in-house 
RIAs as described previously. Insulin was measured by a commercially available RIA 
(Medgenix Diagnostics) 
 
Data analysis 
 
PWV data were not available for 18 women, leaving 384 women for analyses. Results are 
expressed as the mean and SD, unless otherwise stated. The relationships between circulating 
hormones levels and the arterial stiffness measures and other variables were assessed using 
linear regression models and are given as the linear regression coefficient (ß) and its standard 
error (SE). Multiple linear regression analysis was used to adjust for age, heart rate, blood 
pressure and body mass index. Using multiplicative interaction terms, we evaluated whether 
the association of estradiol and PWV differed among smokers and among participants with 
obesity, hypertension and diabetes mellitus. Statistical analyses were done using SPSS for 
Windows (version 11.0). 
 
Results 
 
The characteristics of the subjects are shown in Table 1.  
Circulating hormone levels were not related to age except for DHEA and DHEAS, which were 
both significantly lower when women were older (results not shown). Increasing estradiol levels 
were associated with higher BMI. Higher estradiol levels were associated with higher blood 
pressure levels independently of BMI. After adjustment for mean arterial pressure, or BMI, 
estradiol, estrone, testosterone and SHBG were not related to arterial stiffness (Table 2). 
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 TABLE 1. Characteristics of the study population (n = 384). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as mean (standard deviation) in case of continuous variables,  
and as percentages (number of cases) in case of categorical variables. 
The same analyses performed after exclusion of early menopausal participants showed no material 
changes in the magnitude of above-mentioned associations. No evidence was found for an association 
of estradiol, and estrone to PWV in different strata of smoking, body mass index, hypertension or 
glucose intolerance (p values of interactions terms ≥ 0.15). In the same analysis for SHBG, the p value 
of interaction terms in strata of hypertension and glucose intolerance were significant (p < 0.05). 
SHBG was not associated with PWV in the group with hypertension or with glucose intolerance. None 
of the other circulating hormone levels measured was associated to PWV (Table 2). 
Characteristic Mean (SD) Study population N = 384 
Age (year) 66.2 (3.8) 
Time since menopause (year) 16.9 (6.3) 
Age at menopause (year) 49.7 (4.5) 
Age at menarche (year) 13.5 (1.6) 
Body Mass Index (kg/m²) 26 (4.2) 
Waist-to-hip ratio (cm/cm) 0.81 (0.07) 
      Cardiovascular risk factors 
 
Systolic blood pressure (mmHg) 147.7 (20.8) 
Diastolic blood pressure (mmHg) 76 (13.6) 
Mean arterial pressure (mmHg) 100 (14.8) 
Pulse pressure (mmHg) 71.8 (14.3) 
Heart rate (bpm) 69 (10) 
Smoker %(n) 13 (50) 
Past smoker %(n) 36.5 (140) 
Total cholesterol (mmol/l) 6.3 (1) 
HDL-cholesterol (mmol/l) 1.5 (0.4) 
LDL-cholesterol (mmol/l) 4.1 (1) 
Hypercholesterolemia % (n) 53 (203) 
Triglycerides (mmol/l) 1.45 (0.7) 
Serum glucose (mmol/l) 5.2 (1.2) 
Insuline (mU/l) 11.5 (7.1) 
Diabetes mellitus % 7.3 (28) 
Hypertension % (n) 37 (143) 
Cardiovascular disease % (n) 11 (43) 
Hormones  
Estradiol (pmol/l) 20.2 (13.3) 
Estrone (pmol/l) 46.5 (36) 
SHBG (nmol/l) 59.06 (26.9) 
Testosterone (nmol/l) 1.96 (0.8) 
Androstenedione (nmol/l) 3.4 (1.5) 
DHEA (nmol/l) 13.3 (8.1) 
DHEAS (umol/L) 2.3 (1.4) 
Cortisol (nmol/L) 463.1 (140) 
Insulin (mU/l) 11.8 (7.2) 
IGFBP-1 mg/l 34.7 (28) 
IGF-1 (nmol/l) 17.9 (7.2) 
IGFBP-3 mg/l 3.3 (0.6) 
Pulse wave velocity (m/s) 9.2 (2.2) 
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Discussion 
 
This study investigated the association between remaining endogenous estrogens, 
testosterone and sex hormone-binding globulin and arterial stiffness among women who had 
experienced their last menstruation between 8 and 30 years ago. Endogenous estrogens and 
SHBG levels did not change with age, age at menopause or time since menopause in this 
population. This is consistent with previously reported data on postmenopausal serum sex 
steroid concentrations, where a relative stability of intra-individual estrone and estradiol 
levels was shown from 3 years after the postmenopausal decline 11-13. No association was 
found between the remaining endogenous hormones levels measured and arterial stiffness. 
This may be due to an unexpected association of higher estradiol level with higher blood 
pressure in our population which might have counteracted a beneficial effect of estrogens on 
distensibility if present at all. The analysis of the association is complicated by the fact that 
postmenopausal estrogen production primarily depends on body weight, the latter being a 
strong determinant of blood pressure and atherosclerosis as well.  
Strong evidence supports the hypothesis that a longer exposure to premenopausal levels of 
endogenous estrogens protects against cardiovascular diseases en that estrogens might be 
implicated in short-term protective effects on arterial distensibility by interacting with 
endothelial function as a local modulator, and in long-term effect by influencing structural 
arterial wall modifications (elastin/collagen ratio) 14-16. Vascular stiffness arises as a result of 
age-related and irreversible degenerative arteriosclerotic changes. The age related increase of 
pulse wave velocity is due to physiological degeneration of elastic fibers with parallel 
increase in collagen and mucopolysaccharides within the media, and accumulation of vascular 
smooth muscle cells in the arterial wall 17-19. A number of studies have shown that the normal 
decline in endogenous estrogen production during the menopausal transition period is related 
to increased arterial stiffness 20-23 which can be prevented or delayed by hormonal therapy 
(HT) 24. Furthermore, several studies in postmenopausal women have demonstrated that the 
administration of estrogen has short-term vascular effects, including dilatation of coronary 
arteries, improvement of the elastic properties of the aorta and reduced wave reflection in the 
arterial periphery 25,26.  
The absence of associations found in our study is not necessarily in contradiction with 
possible protective effects of estrogens on arterial stiffness. If irreversible structural 
modifications of the arterial wall occur during exposition to low serum estrogens 
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concentrations, considering the fact that our participants experienced menopause 8 to 30 years 
ago, endogenous estradiol levels have probably been too long far below a threshold at which 
any beneficial arterial effect can be demonstrated. The findings of the WISE study where 
disruption of ovulatory cycling characterized by hypoestrogenemia of hypothalamic origin 
appears to be associated with angiographic coronary artery disease among premenopausal 
women support this view 27. Hypoestrogenemia was defined as estradiol < 184 pmol/l, 
whereas in our study mean estradiol levels were 20 pmol/l. 
 Furthermore, the endothelium-dependent vasodilating effect of estrogens may also be less 
apparent on large arteries especially if stiffening has already occurred within the media. HT 
started a long time after menopause seems not to be related to lower arterial stiffness 28,29. 
This view is supported by the findings from different studies, in particular the Cardiovascular 
Health study, the Prevention Atherosclerosis Trial (EPAT), the Estrogen Replacement and 
Atherosclerotic trial and even in the HERS study, where greater vasodilatation effects of 
estradiol were found among hormone replacement users without cardiovascular disease, 
compared to hormone users with established coronary artery disease or non hormone users 30-
35
. Neither vasodilating effects of estradiol nor effects on the progression of atherosclerosis 
have been demonstrated among women with established atherosclerosis, while those effects 
were present among women younger than 45 year without pre-existent cardiovascular disease 
30-35
.  
Findings in animal studies also suggest that estradiol has little anti-atherosclerotic effects 
in the presence of established coronary artery disease. Hormone therapy started two years 
after oophorectomy produced no effect on the extent of coronary artery plaque formation, 
while similar hormone treatment administered to monkeys immediately after surgery resulted 
in a 50% reduction in atherosclerotic development 36. The WHI study results also support the 
argument that the population was already too old to expect a beneficial effect of estradiol 
administration. The conflicting results about benefit and risks of HT among postmenopausal 
women can be explained by the previously discussed possibility that it only prevents onset 
and progression of atherosclerosis when started before the occurrence of major vascular 
damage, and may work adversely in the presence of generalized atherosclerosis with 
occurrence of clinical events 37,38.  
The relation observed between SHBG and arterial stiffness is interesting and not fully 
understood. Synthesized in the liver, SHBG levels regulate plasma free and protein-bound 
androgens and estrogens. SHBG decreases with increasing visceral fat, triglyceride and 
insulin concentrations, and increases with higher levels of HDL cholesterol. Therefore, SHBG 
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seems to be an important and reliable marker of the interrelationships between sex steroid 
hormones, obesity, and cardiovascular disease risk 39-42. Recently, SHBG has been shown to 
mediate extra-cellular steroid hormone actions after binding to specific high affinity SHBG 
receptors 43. However, it is not known whether an intrinsic protective effect on the arterial 
wall works through SHBG-receptors. 
In conclusion, in this study among postmenopausal women having experienced last 
menstruation between 8 and 30 years ago, the remaining endogenous estrogen levels are not 
associated with aorta stiffness. 
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Abstract 
Objective: To investigate whether levels of endogenous hormones, in particular circulating 
oestrogens and SHBG, are associated with cognition in healthy postmenopausal women. 
Design: Cross-sectional study 
Patients: 402  healthy postmenopausal women aged 56-73 years between 8 and 30 years after 
menopause, none taking oestrogen.  
Measurements: Serum concentration of oestradiol, oestrone, and sex hormone binding globulin 
(SHBG) determined by immunoassay. Cognition assessed using the mini-mental state examination 
questionnaire (MMSE). 
Results: In this group, 149 individuals had a MMSE score < 27, while only 89 individuals had a 
MMSE score < 26, indicating a relatively healthy population with regard to cognitive ability. 
Cognition decreased with age, time since menopause and blood pressure, and was better with higher 
age at menopause. Serum oestrogens and SHBG levels were not related to age, age at menopause, or 
time since menopause, and oestrogen levels were positively associated with blood pressure. After 
adjustment for mean arterial pressure and SHBG, the frequency of mild cognitive impairment 
decreased significantly with higher oestradiol and oestrone serum levels [ORs Q5 versus Q1: 0.41 
(95% CI 0.20-0.84) and 0.51 (95% CI 0.20-0.99) for oestradiol and oestrone, respectively]. 
Conclusions: Postmenopausal women with higher remaining circulating oestradiol levels appear 
less likely to suffer from cognitive impairment. This effect is independent of age at menopause, time 
since menopause and BMI. These findings support the hypothesis that endogenous oestrogens may 
protect against cognitive decline with aging. 
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Introduction 
 
An increase of life expectancy is not necessarily accompanied by a similar increase in 
healthy life span, and understanding determinants of successful aging and in particular the 
role played by endocrine factors has gained increased interest 1. Women are likely to live a 
third of their lives in a state of relative oestrogen deficiency, which is held responsible for 
unfavourable long-term effects on bone metabolism, the cardiovascular system, and probably 
cognitive function culminating in dementia. There is growing evidence that oestrogens impact 
on memory, affect, and motor co-ordination in women, and they also appear to have a 
neuroprotective effect for Alzheimer’s disease 2;3. In contrast, results from studies with 
hormonal replacement therapy (HRT) have not supported a protective effect of exogenous 
oestrogens on cognitive functions. 4-6 A few studies have addressed the role of the remaining 
circulating postmenopausal oestrogens in cognition, but were hampered by small sample sizes 
or improper adjustment for potential confounders. 7-10 Two studies reported protective effect 
of higher oestradiol levels on cognitive decline 3,11 while a recent study found that higher 
serum oestradiol levels were associated with a higher risk of Alzheimer’s disease. 12  
The aim of this study was to determine the relation between circulating oestrogen 
measured with new more sensitive methods and sex hormone binding globulin levels and 
cognition in healthy postmenopausal women. 
 
Subject and methods 
 
Study population 
 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC).13 
In PROSPECT a total of 17,395 healthy participants who came for breast cancer screening, 
aged 49-70 years, living in Utrecht and surroundings, were enrolled between 1993 and 1997. 
Using baseline data from PROSPECT, we selected women who had experienced a natural 
menopause between 8 to 30 years ago. In addition, inclusion criteria were an intact uterus and 
at least one intact ovary, and no use of sex steroids after the reported date of last menstruation. 
Out of 1803 eligible women, 902 women were invited and 553 (61%) answered positively. 
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402 participants were finally included in our study. Women were considered sufficiently 
healthy to participate when they were physically and mentally able to visit the study centre 
independently. Each participant underwent all tests and assessments during two visits to the 
study centre. The study was approved by the Institutional Review Board of the University 
Medical Centre, Utrecht, and written informed consent was obtained from all participants. 
Data collection took place between September 1999 and March 2000. 
 
MMSE  
Cognitive function was assessed by specially trained research assistants using the Dutch 
version of the 30-point Mini- Mental State Examination questionnaire (MMSE). 14 This short 
general cognitive test has been used extensively in epidemiological studies and allows 
assessment of orientation to time and space, concentration, language, calculation, and 
immediate and delayed memory. Among older people a score below 24 indicates cognitive 
impairment. Because of our selection of a relatively young population, with exclusion of 
disabled and those dependent on others for activities of daily living, we did not expect any 
woman participating in this study to qualify for the definition of clinical dementia. We used 
two different cut-off points, the widely used threshold of 26 below which moderate cognitive 
impairment is defined, 15 and a threshold of 27 below which mild cognitive impairment was 
considered to occur. 
 
Biochemical assessments 
 
Venous blood samples were collected in the morning between 8.00 and 11.00 a.m. after an 
overnight fast. Levels of oestradiol were estimated using an ultra-sensitive double-antibody 
radioimmunoassay (RIA) purchased from Diagnostic Systems Laboratories (Webster, TX, 
USA). Oestrone levels were measured using a double antibody RIA from the same supplier. 
SHBG was measured using a chemoluminescence based immunometric assay on the Immulite 
2000 system (Diagnostic Products Corporation, Los Angeles, CA, USA).  
 
Other measurements 
 
Information on health status was obtained by medical history, registration of current 
medication and physical examination. A standardised questionnaire on oestrogen use, alcohol 
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consumption and smoking was obtained from all women as part of the medical history. 
Subjects were categorised in current smokers, former smokers and those who had never 
smoked. Height, weight, waist and hip circumference were measured with the subject in 
standing position wearing indoor clothes and no shoes. Body mass index (BMI) was 
calculated as the weight in kilograms divided by the square of the height in meters, and body 
fat distribution was assessed by the ratio of waist and hip circumferences. Blood pressure and 
heart rate were measured during the first visit by the oscillometric automated device 
DINAMAP 8100 (Critikon, Johnson-Johnson, Tampa, FL, USA) according to the orthostatic 
hypotension protocol. 16 Measurements were conducted before 11.00 a.m. after an overnight 
fast. 17 After five minutes of rest, blood pressure was taken at the right brachial artery 
simultaneously with heart rate measure, twice with the participant lying down and three times 
with the participant in standing position, with a time laps of one minute between each 
measurement. Systolic as well as diastolic blood pressure was defined as the average of the 
two supine measurements. Mean arterial blood pressure (MAP) was calculated by the 
following formula: diastolic blood pressure + 1/3 x (systolic blood pressure – diastolic blood 
pressure). 
 
Data analysis 
 
Distributions of population characteristics are expressed according to the quintile 
distributions of oestradiol level. Associations between sex steroid levels and cognition were 
quantified using logistic regression models and odds ratios and their 95% confidence intervals 
are presented. Adjustments were made for age and other potential confounders. Statistical 
analyses were done using SPSS for Windows (version 11.0). 
 
Results 
 
General characteristics of the entire study population and according to the quintile 
distribution of oestradiol serum levels are given in Table 1. 
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Increasing oestradiol levels were associated with higher BMI and waist circumference 
consistent with adipose tissue being an important source of postmenopausal oestrogen 
production. Oestrogens were also associated with increasing blood pressure independently of 
BMI. Circulating oestradiol and oestrone levels were not associated to age, age at menopause, 
time since menopause or educational level of participants. 
The distribution of MMSE scores is given in Fig. 1, and the educational level of participant 
is shown in Fig. 2. 
 
 
 
 
The frequency of cognitive impairment increased with age, with time since menopause, 
and with higher blood pressure, and both levels of cognitive impairment were decreasing with 
higher age at menopause and with higher educational level of participants (Table 2). The 
frequency of cognitive impairment was not related to BMI or fat mass, even after adjustment 
for blood pressure and/or age.  
A slight decrease in the frequency of cognitive impairment was seen with increasing 
quintiles of oestradiol concentration (Table 1) and higher oestradiol and oestrone levels were 
significantly associated with lower frequency of mild cognitive impairment (MMSE<27) 
(Table 3). These associations were stronger after adjustment for mean arterial blood pressure 
and/or SHBG, and remained unchanged after adjustment for BMI, and educational level. 
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Analyses with moderate cognitive impairment (MMSE<26) showed essentially the same 
results, with variations explained by the smaller number of women in this category (Table 4). 
Further adjustment for other possible confounders did not significantly change the 
associations. Sex hormone-binding globulin was not related to the level of cognitive decline. 
The same analyses performed after exclusion of early menopausal women (age at menopause 
≤ 45 year) showed virtually the same results. 
 
Table 2: Determinants of impaired cognition  
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Discussion 
 
The results of this study among healthy women 8 to 30 years after menopause suggest that 
higher circulating oestrogen concentrations (predominantly oestradiol) are associated with a 
lower risk of cognitive decline. This effect was more pronounced after adjustment for blood 
pressure and SHBG, and was independent of BMI. 
Before interpreting these data, some issues need to be addressed. We used the MMSE test 
to evaluate cognitive function because of its wide use and simplicity to be performed on a 
large scale allowing subjective interpretation to be avoided. A cut-off value of 26 points was 
chosen to mark intact cognition because our objective was to determine cognitive function 
rather than to diagnose dementia. 18 Although detection of subtle cognitive change or specific 
cognitive function testing are not possible with the MMSE, its validity and usefulness as a test 
for overall cognitive screening has been well documented 19,20. On an individual level the 
MMSE is probably not a very precise test to assess cognitive function, but on a population 
level it adequately reflects the distribution of cognition. 21 Because of a small number of 
women with MMSE<26 in this relatively healthy group of independently living women in 
which individuals with clearly impaired cognition were excluded at the start of the study, we 
used a threshold of 27 below which mild cognitive impairment was considered to occur. Both 
cognitive impairments analyses showed essentially the same results, with variations in 
significance explained by the smaller number of women in the category below 26.  
There is a moderate increase of MMSE score with increasing quintiles of oestradiol 
concentration in this population. Although associations between higher oestrogen levels and 
lower frequency of mild cognitive impairment were significant, a risk of over interpretation 
cannot be totally excluded. It is once again stressed that this cross-sectional study was carried 
out in a group of menopausal women in relative health and of relatively good cognition. 
Our findings are consistent with previously reported postmenopausal evolution of sex 
steroids serum concentrations, with intra-individual oestrone and oestradiol levels remaining 
relatively stable from 3 years after the postmenopausal decline. 22-24 The principal source of 
oestrogens in postmenopausal women is peripheral aromatisation of androstenedione to 
oestrone in adipose tissue and skin, which is subsequently reduced to oestradiol in peripheral 
tissues. Extragonadal oestrogen biosynthesis occurs in a number of sites, including adipose 
tissue, bone, various sites of the brain, and vascular endothelial and smooth muscle cells. 25 
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Postmenopausal oestrogen production is thus primarily influenced by body weight but not by 
age.  
The protective effect of oestrogens on cognitive decline was more pronounced after 
adjustment for SHBG, suggesting that the bioavailable oestrogen level is the principal 
determinant for an effect on the brain. This is consistent with the findings of Yaffe et al.3 in 
425 postmenopausal women 65 years and older, but not with the findings of Drake et al.11  in 
a smaller group of 39 postmenopausal women aged 65 to 90 years, mean 78.8 ± 7.1 (SD). 
Apart from a lower power in the study of Drake et al.,11 adjustment for SHBG probably better 
estimates oestrogen activity, apart from a possible additional intrinsic effect of SHBG. Recent 
evidence has shown that SHBG bound to specific SHBG receptors might promote steroid 
activity by activation of adenylate cyclase, thus without steroids entering the cell. 26 In both 
studies mentioned above3,11 blood pressure was not measured. However, we found this to be a 
probable confounding factor in the relation between circulating oestrogen levels and cognitive 
decline, which could have weakened the association between oestradiol and cognition. 
Interestingly, in our population serum oestradiol levels increased with BMI and frequency 
of impairment in cognitive functions decreased with higher serum oestradiol levels, but higher 
BMI did not protect against cognitive impairment. Fat mass or higher BMI was not related to 
cognition, which suggest the importance of other sources of oestradiol production than 
adipose tissue in postmenopausal women. Also local oestrogen biosynthesis by aromatase 
activity in the brain may be important in the regulation of various cognitive and hypothalamic 
functions.27 Simpson28 and Labrie29 have hypothesised that in postmenopausal women, and 
also in men, extragonadal oestradiol plays an important paracrine, autocrine and indeed, 
intracrine role.  
Our findings do not agree with a recent study where higher oestradiol levels were 
(although not significantly) associated with higher risk of dementia. 12 Two other studies on 
Alzeimer disease (AD) patients found the same trend, one with higher oestrone and 
androstenedione levels in the AD group, 10 and the other with not significantly increased 
levels of oestradiol in the AD group compared to healthy elderly.9 AD is associated with a 
disorder of the hypothalamic-pituitary-adrenal (HPA) axis and with increased levels of 
adrenocortical and gonadal hormones. The hypothesis that AD itself could be responsible for 
an abnormality of sex steroid production has been previously mentioned and deserves further 
investigation. 9,10 
In conclusion, postmenopausal women with higher “remaining” oestradiol levels appear 
less likely to suffer from cognitive decline. This effect seems independent of age at 
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menopause, time since menopause or body mass index, and stronger after adjustment for 
blood pressure. The findings of this study support the hypothesis that higher postmenopausal 
endogenous oestrogen levels may protect against cognitive impairment. 
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Abstract 
Objective: The aim of this study in healthy postmenopausal women was to determine the 
variations of effect on bone mineral density at various sites of the following determinants: fat mass, 
lean mass, appendicular lean mass and muscle strength, and endogenous hormones. 
Method: We performed a cross-sectional study among 402 randomly selected women aged 56-73 
years, not using exogenous hormones. Serum concentrations of estradiol (E2), estrone (E1), 
testosterone (T) and sex hormone-binding globulin (SHBG) were determined by immunoassay. Bone 
mineral density and body composition including lean mass and fat mass were assessed using dual-
energy x-ray absorptiometry at the following sites: the whole body, skull, arms, legs and the total hip. 
We measured grip and knee muscle strength using dynamometry. To compare the strength of effects 
of various determinants, we used standardised β of linear regression. 
Results: Well-known determinants of BMD were confirmed. For whole body BMD, lean and fat 
mass were equal independent determinants, but at local sites, BMD was mainly determined by total fat 
mass (standardised β of linear regression 0.21 to 0.32) followed by total lean mass (0.19 to 0.24). Skull 
BMD was further determined by circulating estradiol level (0.14), while weak and not significant 
effects of muscle mass and strength were observed. Grip force was strongly associated with arm BMD 
(0.21), while the relation with leg extensor strength and arm BMD was dependent on appendicular 
lean mass (0.19). Serum estradiol was also independently related to arm BMD (0.13). Other 
independent determinants of hip BMD were leg muscle strength (0.24) and appendicular lean mass 
(0.14), while no significant relation was found with estradiol. 
Conclusions: The postmenopausal changes in body composition have considerable effects on 
BMD determinants. Fat mass plays the major role, followed by lean mass. We present evidence for 
specific local effects of lean mass en muscle strength on arm and hip BMD. The effect of circulating 
estradiol was predominantly localized at the skull and the arm. 
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Introduction 
 
Postmenopausal women all share a drop in circulating estrogen level, known to be 
associated with decreased bone mineral density (BMD) and increased risk of osteoporotic 
fractures, a significant cause of disability among postmenopausal elderly women in Western 
societies. The increasing life expectancy augments the time span lived in a postmenopausal 
state of relative estrogen deficiency and the consecutive unfavorable effects on bone 
metabolism may reduce the chance of living an independent life until death 1. There is 
however much variation between women in tendency of suffering from osteoporotic fractures. 
Differences in remaining serum levels of estradiol might in part explain this variation, with 
evidence that estradiol levels under a given threshold are strongly associated with rapid bone 
loss and sudden increased risk of fractures 2,3. In addition, sex hormone binding globulin 
(SHBG), which determines free levels of sex steroid hormones, may also play a substantial 
role in postmenopausal estrogen physiology. The age related decrease of BMD is known to be 
attenuated by higher body mass index, serum estrogen levels 2,4,5, and muscle strength 6-9. A 
protective effect of muscle strength and physical exercise on BMD has also been 
demonstrated 10-12. However, the mechanisms by which these determinants are leading to 
changes on BMD among postmenopausal women as well as their respective roles are not fully 
understood. As far as we know, a site-specific analysis of BMD determinants has only be 
done for muscle strength and lean mass 13,14. Additional insight in the specific local effects of 
these factors is of etiological interest and might have implications in the prevention of 
osteoporotic fractures. 
The aim of this study was to investigate the local effects of fat and lean mass, muscle mass 
and strength, and endogenous estrogens and SHBG on the whole body, skull, arms and hip 
BMD in healthy women having experienced menopause 8 to 30 years ago. 
 
Subject and methods 
 
Study population 
 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) 15. 
In PROSPECT a total of 17,395 healthy participants who came for breast cancer screening, 
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aged 49-70 years, living in Utrecht and surroundings, were enrolled between 1993 and 1997. 
Using baseline data from PROSPECT, we selected women who had experienced a natural 
menopause between 8 and 30 years ago. In addition, inclusion criteria were an intact uterus 
and at least one intact ovary, and no use of sex steroids after the reported date of last 
menstruation. Out of 1803 eligible women, 902 women were invited and 553 (61%) answered 
positively. Four hundred and two participants were finally included in our study. Women 
were considered sufficiently healthy to participate when they were physically and mentally 
able to visit the study center independently. Each participant underwent all tests and 
assessments during two visits to the study center. The study was approved by the Institutional 
Review Board of the University Medical Center, Utrecht, and written informed consent was 
obtained from all participants. Data collection took place between September 1999 and March 
2000. 
 
Measurements 
 
Information on health was obtained by medical history, registration of current medication 
and physical examination. Height, weight, waist, and hip circumference were measured with 
the subject in standing position wearing indoor clothes and no shoes. Body mass index (BMI) 
was calculated as the weight in kilograms divided by the square of the height in meters. 
 
Bone mineral density and body composition 
 
Bone mineral density and body composition were measured using dual energy x-ray 
absorptiometry (DXA) (Hologic QDR1000, Hologic Europe, Zaventem, Belgium). Total 
body DXA scan allows the simultaneous determination of regional quantities of three distinct 
compartments: bone mass, fat mass and lean body mass, the sum of these giving the total 
body weight. Using the default Hologic definitions we could get beside total body BMD, fat 
en lean masses, separate measures of these compartments for the skull, arms and legs 16. Hip 
BMD was measured at the proximal femur, the femoral neck, the greater trochanter, and 
Ward’s triangle. Standard positioning was used with the left proximal femur. If there was a 
history of left sided prosthesis implantation, the right femur was scanned. Quality control 
including calibration, was performed every morning, using the standard provided by the 
manufacturer. 
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Fat mass and lean mass percentages were calculated dividing total fat or lean mass (kg) by 
body weight (kg) multiplied by 100. Appendicular fat mass and appendicular lean mass 
(ALM) were calculated as the sum of legs and arms fat and lean mass as described by 
Heymsfield et al 17. DXA-estimated appendicular lean mass comprises muscle and other 
components such as skin, tendons, connective tissues, and the lean portion of adipose tissue. 
 
Hormone measurements 
 
Venous blood samples were collected in the morning between 8.00 and 11.00 a.m. after an 
overnight fast. Serum was separated by centrifugation and deeply frozen. Serum 
concentrations of estradiol (E2, nmol/l), estrone (E1, nmol/l), and total testosterone (T, 
nmol/l) were estimated using commercial ultra-sensitive double-antibody radioimmunoassay 
kits purchased from Diagnostic Systems Laboratories (Webster, TX, USA). Sex hormone 
binding globulin (SHBG, nmol/l) was measured using a chemoluminescence immunometric 
assay on the Immulite 2000 system (Diagnostic Products Corporation, Los Angeles, CA, 
USA). 
 
Muscle strength 
 
Isometric grip strength was measured using an adjustable hand-held dynamometer 
(JAMAR dynamometer) at the non-dominant hand. Each test was done in triplicate, and the 
average was used in the analysis 18. Leg (or knee) extensor strength was measured as 
described previously 1,19, using the Hoggan MicroFET hand-held dynamometer. To obtain 
one main outcome measurement for leg extensor strength, maximum LES (MLES) was 
defined as the maximum strength for the right or the left leg, whichever was largest, in a 
position of 120 degrees extension. Statistical analyses were based on the physical unit 
momentum [Newton meters (Nm)], obtained by multiplying the maximum strength (in N) and 
the distance of the dynamometer to the knee joint (in meters). 
 
Data analysis 
 
Results are expressed as the mean and SD, unless otherwise stated. Independent 
determinants of BMD were determined using multiple linear regression analysis. We further 
69 
Bone mineral density 
analysed the relation between those determinants and BMD at the following sites: total body, 
skull, arms, legs and total hip. Because of the similarity of the results obtained by analyses 
performed with all individual hip BMD measures (femoral neck, Ward’s triangle, and femoral 
trochanter), and with legs BMD, we restricted the presented results to total hip. Associations 
between variables and bone mineral density at different sites were first assessed using a linear 
regression model and multiple linear regression analysis was performed to control for possible 
confounders. In order to compare the strength of the associations between determinants and 
bone mineral density at various locations, we used the standardized beta coefficient. All 
variables - determinants and bone mineral densities - are standardized by subtracting the mean 
and dividing by the standard deviation. When using these variables in the regression 
functions, the resulting standardized regression coefficients represent the change in bone 
mineral density (expressed as a fraction of the standard deviation) for a change of one 
standard deviation in a determinant. Statistical analyses were done using the SPSS 12.0 
statistical package for Windows. 
 
Results 
 
General characteristics of the study population are given in Table 1.  
 
Bone mineral density determinants 
 
Well-known independent determinants of BMD were confirmed. Total body BMD 
decreased with 0.041 ± 0.001 gr/cm²  per 10 years of advancing age, and was higher with 
higher age at menopause and shorter time since menopause. Total body BMD increased with 
a mean of 0.004 ± 0.001 gr/cm² per kg fat mass increase, with 0.0076 ± 0.001 gr/cm² per kg 
lean mass increase, with 0.003 ± 0.001 gr/cm² per N grip strength, and with 0.0012 ± 0.001 
gr/cm² per Nm leg extensor muscle strength (Table 2).  
After adjustment for fat mass, total body BMD increased with 0.008 ± 0.003 gr/cm² per 10 
pmol/l estradiol, and with 0.14 ± 0.05 gr/cm² per 10 nmol/l Testosterone (Table 3). When 
estradiol and testosterone were included in the same model, associations with BMD where 
lost, suggesting a common pathway. Higher SHBG levels were associated with lower total 
body BMD, with a decrease of 0.005 ± 0.003 gr/cm² per 10 pmol/l SHBG. In order to 
investigate the relation between SHBG, BMD and estradiol, we first did a trend analysis 
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between quintiles of SHBG levels and BMD where a threshold of effect around 45 nmol/l was 
seen (Table 3a). Thereafter we compared the effect of E2 on BMD between women with 
SHBG levels < 45 nmol/l with those with SHBG level ≥ 45 nmol/l. The trends of associations 
are shown in table 3b. In the group with low SHBG, only women with estradiol levels < 10 
pmol/l had a lower BMD. In the group with high SHBG, estradiol was linearly and 
significantly related to BMD (Figure 1). 
Table 1. Characteristics of the study population (n = 402). 
Characteristic Mean (SD) Study population 
N = 402 
Age (year) 66.3 (3.9) 
Time since menopause (year) 17.1 (6.4) 
Age at menopause (year) 49.6 (4.5) 
Mean arterial pressure (mmHg) 100 (14.8) 
Body Mass Index (kg/m²) 26.2 (4.4) 
Waist (cm) 82.9 (10.8) 
Fractures after 50 yrs of age  % (n) 22.9 (92) 
Total fat mass (kg) 23.5 (8.4) 
Total lean mass (kg) 44.9 (5) 
    Appendicular lean mass (kg) 17.2 (2.3) 
    Lean mass arms (kg) 3.9 (0.6) 
    Lean mass legs (kg) 13.3 (1.8) 
Fat mass percentage (%) 32.8 (6.5) 
Lean mass percentage (%) 65.1 (6.4) 
Grip force (N) 24.8 (4.8) 
Maximum Leg Extensor Strength (Nm) 119.8 (22) 
Bone mineral density (BMD)  
Total Body Bone Mineral Density (g/cm²) 1.02 (0.09) 
    BMD skull (g/cm²) 1.84 (0.28) 
    BMD dominant arm (g/cm²) 0.74 (0.06) 
    BMD not dominant arm (g/cm²) 0.73 (0.06) 
    BMD arms (g/cm²) 0.73 (0.07) 
    BMD legs (g/cm²) 1.08 (0.12) 
Total hip BMD (g/cm²) 0.83 (0.13) 
    BMD neck of the hip (g/cm²) 0.69 (0.11) 
    BMD trochanter (hip) (g/cm²) 0.64 (0.11) 
    BMD wards triangle (hip) (g/cm²) 0.51 (0.13) 
Hormones  
Estradiol (pmol/l) 20.2 (13.5) 
Non-SHBG bound E2 (pmol/l) 12.7 (9.9) 
Estrone (pmol/l) 45 (36.4) 
SHBG (nmol/l) 59.07 (26.7) 
Testosterone (nmol/l) 1.97 (0.8) 
Non-SHBG bound T (nmol/l) 0.90 (0.5) 
Values are expressed as mean (standard deviation) 
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Table 3a: Relation of quintiles of SHBG with total body bone mineral density 
Full model* ß coefficient  SE  P 
 Quintile 2 shbg (36.5 thru 48.7 nmol/l) -0.0169 0.015 0.254 
 Quintile 3 shbg  (48.7 thru 61.9 nmol/l) -0.0439 0.015 0.003 
 Quintile 4 shbg  (61.9 thru 76.7 nmol/l) -0.0460 0.015 0.002 
 Quintile 5 shbg   (>76.7 nmol/l) -0.0795 0.015 < 0.001 
 
Table 3b : Trend analysis between quintiles E2 and BMD in both SHBG groups 
 
 
SHBG level < 45 nmol/l  ß ± SE  p SHBG level >= 45 ß ± SE p 
 
Total body BMD  0.007 ± 0.006 0.245 0.012 ± 0.004 0.003 
Skull BMD  0.026 ± 0.018 0.146 0.043± 0.011 <0.001 
Arms BMD  0.007 ± 0.004 0.043 0.009± 0.003 0.004 
Legs BMD 0.011 ± 0.008 0.169 0.010± 0.005 0.059 
Total hip BMD  0.017  ± 0.008 0.040 0.003± 0.006 0.547 
ß coefficient reflects BMD changes in gr/cm² per quintile E2*p ≤ 0.05. **p ≤ 0.01. ***p ≤ 0.001. 
 
BMD determinants at different sites 
 
We used the standardised beta coefficient with standard error to compare the strength of the 
associations between the determinants mentioned above and bone mineral density at various locations. 
The results are shown in figure 2. At all locations, BMD was mainly determined by total fat mass 
(standardised β of linear regression  between 0.21 and 0.42) and total lean mass (0.14 to 0.24). Local 
differences were found for estradiol, appendicular lean mass and muscle strength. Skull BMD was 
further determined by circulating estradiol level (0.14), while weak and non significant effects of 
muscle mass and strength were observed. At the arm, grip force (0.21) was strongly associated with 
higher BMD, the relation with leg extensor strength being weak and dependent on appendicular lean 
mass (0.19). Serum estradiol was also independently related to arm BMD (0.13). Independent other 
determinants of higher leg and hip BMD were leg muscle strength (0.22 and 0.24) and appendicular 
lean mass (0.20 and 0.14), while no significant relation was found with estradiol. The relation with 
grip strength at those sites was lost after adjustment for appendicular lean mass. 
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Figure 1. Relation between quintiles estradiol and BMD at different sites within both 
SHBG groups. 
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  Relative contribution of determinants at different sites 
 
In order to analyse the relative contribution of the different determinants at various sites 
standardised beta coefficient were estimated in a multiple regression model containing age, fat 
mass, total or appendicular lean mass, grip or leg muscle strength, and estradiol (Table 4).  
The negative effect of age was more pronounced at arm-BMD site. Total fat mass and lean 
mass were both independently associated with BMD, with a stronger effect of fat mass on 
BMD at most sites. The Pearson correlation between appendicular lean and total lean mass 
was 93%, and putting both determinants in the same model demonstrates a dominant effect of 
lean mass on total body and skull BMD, suggesting the presence in lean mass of other 
important factors influencing BMD (Table 4).   
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Discussion 
 
In this cross sectional study among healthy women aged 56 to 73 years, 8 to 30 years after 
menopause, whole body BMD decreased with age, and increased with higher fat mass, lean 
mass, muscle strength, higher circulating levels of estradiol and lower levels of SHBG. Fat 
mass was found to be at equal strength with lean mass in terms of its effect on whole body 
BMD, but fat mass seems to be the major determinant of BMD at the local sites studied. 
Differences were present for the other determinants according to the site considered. Skull 
BMD was mainly determined by circulating estradiol level and total lean mass, but not 
significantly by appendicular lean mass, total skeletal muscle mass or SHBG. Interestingly, 
the relation with lean mass was independent of muscle mass. At the arm and hip locations, the 
contribution of appendicular lean mass to BMD was stronger than that of total lean mass. Grip 
strength was independently related to arm BMD and leg extensor muscle strength to hip 
BMD. The respective associations of leg extensor strength with arm BMD and of grip 
strength with hip BMD were dependent on lean mass, supporting a direct and local role of 
strength on stimulation of bone formation at those sites. 
Our results are consistent with previously reported data concerning the determinants of 
bone mineral density among postmenopausal women: age, BMI, estrogens, and muscle 
strength 6-9 and they add a detailed insight in the strength of their effect at various locations. 
Also consistent with our results, earlier studies have provided support for the presence of site-
specific effect of muscular strength on bone 11,13,14,20. Bone bending strength adaptation to 
mechanical loading represented by lean mass and physical activity is the probable way of 
action21,22. Furthermore, skull BMD has been shown to be an interesting bone location 
because it is less sensitive to mechanical influences 23-25. 
Lean mass has been shown to be the most important predictor of bone mass compared to 
fat mass in men 26, in premenarcheal girls 27 and in pre- and perimenopausal women 28,29. In 
postmenopausal women, lean mass and fat mass become equally important contributors to 
BMD 21,30-32.  
Estrogen deficiency at menopause is a major factor in the development of osteoporosis. 
The associated loss of trabecular bone mass and structure leads to an increased incidence of 
postmenopausal osteoporotic fractures 33. The mechanisms by which skeletal effects of sex 
steroids are mediated are not completely understood. Even after menopause, circulating levels 
of the biologically active estrogen, estradiol, seem to play an important role in bone mineral 
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density 2,4. Postmenopausal estradiol is produced by aromatization of androstenedione to 
estrone in adipose tissue and skin, which is subsequently reduced to estradiol in peripheral 
tissues 34. Moreover, all enzymes necessary for estrogen metabolism have been shown to be 
expressed and to be biologically active in differentiating human osteoblasts 35. Increasing 
circulating levels of estradiol and increasing local estrogen concentrations in bone can slow 
down the rate of postmenopausal bone loss. Furthermore, administration of DHEA to 
postmenopausal women showed beneficial effects on bone mineral density through 
transformation of the precursor steroid DHEA into androgens and/or estrogens in specific 
peripheral intracrine tissues 36,37.  
The stronger effect of estrogens at the arm location shown in our study can be explained by 
the preferential trabecular bone-sparing effect of estrogen, considering the higher proportion 
of trabecular bone at this site 38. The threshold for effect of estrogen deficiency in cortical 
bone in women appears to be lower than that in trabecular bone 39,40. The loss of trabecular 
bone soon after ovariectomy occurs by allowing bone formation to continue in previously 
activated bone remodelling units while suppressing the production of new remodelling units. 
Hormone therapy reduces bone turnover significantly after ovariectomy, resorption being 
suppressed more than formation and restores bone density, but not trabecular connectivity. 
This may be the mechanism by which prompt intervention with estrogen and other 
antiresorptive agents can restore bone mass that has been lost as result of the increase in 
remodelling space 41. Also in an animal study, trabecular bone connectivity and volume have 
been shown to deteriorate rapidly in acute estrogen deficiency, supporting the importance of 
treatment institution very early in the estrogen-deficient state to preserve fully trabecular bone 
structure42. 
Small variations in endogenous serum estradiol and high serum SHBG have been shown to 
result in differences in BMD and rate of bone loss in elderly women and to affect the response 
to treatment with estrogen. Accordingly, women with a low serum estradiol level are optimal 
candidates for estrogen therapy for osteoporosis prevention 43. A clear relation exists between 
fat mass and serum estrogen levels. A 12-month moderate-intensity exercise intervention 
study in postmenopausal women resulted in significant decreases in serum estrogens, an effect 
which was limited to women who lost body fat 44. Plasma SHBG levels decrease with higher 
fat mass while insulin also suppresses SHBG levels 45-47. The great influence of fat mass on 
BMD is most likely due to the combination of a number of factors: the known direct 
modulation of bone cell function by the mechanical load resulting from a greater weight, 
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together with a greater conversion of androgens to estrogens in adipocytes, and a decrease in 
SHBG level resulting in a higher concentration of free levels of sex steroids. 
In conclusion, the present study among healthy postmenopausal women confirms the major 
role of fat mass on BMD at all sites and demonstrates the presence of a local stimulation of 
appendicular lean mass and muscle strength on appendicular BMD. Furthermore, skull BMD 
seems to be mainly influenced by circulating estradiol and by lean mass independently of 
muscle mass. Finally the effects of circulating estradiol levels were weak at leg and hip BMD 
sites. The preponderant role of fat mass is probably due to the combination in this group of 
healthy postmenopausal women of an increased peripheral aromatization, a decrease in SHBG 
level and a mechanical load stimulating the maintenance of bone mass. This suggests that the 
postmenopausal changes in body composition have great consequences for BMD 
determinants. 
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Chapter 5 
 
Body composition and development of 
disability 
 
Body composition 
Fat mass rather than muscle strength is the 
major determinant of physical function and 
disability in postmenopausal women 
younger than 75 years of age 
 
Menopause 13, 3  474-481 2006 
 
Abstract 
Objective: Few studies have investigated the relations between body composition, functional 
ability and age-related disability in postmenopausal women. We investigated the relative role of fat 
mass, lean mass, and muscle strength in the development of disability in a group of healthy 
postmenopausal women younger than 75 years. 
Design: We performed a cross-sectional study among 396 independently living women aged 56-
73 years, randomly selected between 8 and 30 years after menopause. Lean mass and fat mass were 
assessed by dual-energy x-ray absorptiometry. Muscle strength (grip and leg extensors) was assessed 
using dynamometry.  Functional ability was estimated by Physical Performance Score, physical 
activity during the preceding year, and impairment in activities of daily living. 
Results: 43.7 % of participants were overweight (25 ≥ BMI < 30 kg/m²), and 17.7 % were obese 
(BM I ≥ 30 kg/m²). Higher muscle strength was observed with increasing lean body mass, and 
participants with higher muscle strength scored better in the physical performance score and ADL.  
Higher fat mass was significantly associated with a lower physical performance score, a lower 
physical activity and a higher frequency of disability. Increasing fat mass went together with 
increasing lean mass, and decreasing lean/fat ratio. The increase of lean mass and muscle strength 
associated with higher fat mass was mainly localized in the legs.  
Conclusions: Our results support the role of fat mass as the primary risk marker for disability, 
which might later accelerate by the age-related decrease in lean mass and the development of 
sarcopenia after the age of 75 years. 
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Introduction 
 
The aging process is accompanied by a gradual loss of physical capacity, mobility, balance 
and endurance, which eventually may result in the loss of living an independent life until 
death1. Muscle mass is the main determinant of sex-related differences in strength, and a 
decrease in muscle mass - in terms of muscle size as well as of number of muscle fibers - is 
the main reason for the decline in muscle strength during aging 2,3. Due to the loss of skeletal 
muscle, the aging body is less able to resist protein catabolism induced by acute illness or 
inadequate protein intake, and loss of skeletal muscle mass is considered to be the most 
important determinant of functional impairment and disability in the elderly 4-6. A second 
mechanism which might contribute to the decrease in physical function is the age-related 
change in muscle composition due to fat infiltration as well as an increase in fat mass that is 
redistributed from a peripheral to a central location7. In several studies in elderly individuals a 
higher level of disability was demonstrated with increasing BMI or fat mass8-14.  
Studies investigating the association between low muscle mass and physical function have 
shown inconsistent results11,12,14,15. In many studies the percentage of muscle mass has been 
used, making it difficult to recognize the role played by fat mass in the development of 
physical impairment16. The use of calculated values of muscle mass might also explain some 
of the inconsistent results in previous studies6,14,16. 
The aim of our study was to investigate in more detail the relative contribution of muscle 
and fat mass and their regional distribution, as directly measured by dual-energy x-ray 
absorptiometry (DEXA), to the physical functional status and the development of disability in 
a large group of healthy independently living postmenopausal women between the age of 56 
and 74 years. 
 
Materials and methods 
 
Subjects 
 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC)17. In 
PROSPECT a total of 17,395 healthy participants who came for breast cancer screening, aged 
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49-70 years, living in Utrecht and surroundings, were enrolled between 1993 and 1997. Using 
baseline data from PROSPECT, we selected women who had experienced a natural 
menopause. In addition, women should have an intact uterus and at least one intact ovary and 
should not have used sex steroids after the reported date of last menstruation. Out of 1803 
eligible women, 902 women were invited and 553 (61%) answered positively. Four hundred 
and two participants were finally included in our study. Women were considered sufficiently 
healthy to participate when they were physically and mentally able to visit the study centre 
independently. Each participant underwent all tests and assessments during two visits to the 
study centre. The study was approved by the Institutional Review Board of the University 
Medical Center Utrecht and written informed consent was obtained from all participants. Data 
collection took place between September 1999 and March 2000. 
 
Measurements 
 
Information on health was obtained by medical history, registration of current medication 
and physical examination. Height, weight, waist and hip circumference were measured with 
the subject in standing position wearing indoor clothes and no shoes. Body mass index (BMI) 
was calculated as the weight in kilograms divided by the square of the height in meters, and 
body fat distribution was also assessed by calculating the ratio of waist to hip circumferences. 
Overweight was defined as BMI ≥ 25 and < 30 kg/m², and obesity as a BMI ≥ 30 kg/m² 18. 
Comorbidity was categorized as no chronic conditions, one chronic condition or two or more 
chronic conditions, based on medication use and self-reported physicians’ diagnosis of 
cardiovascular disease, stroke, diabetes mellitus, COPD, and severe osteoarthritis. 
 
Body composition 
 
Body composition was assessed using dual energy x-ray absorptiometry (DXA) (Hologic 
QDR1000, Hologic Europe, Zaventem, Belgium). This allows the simultaneous measure of 
three distinct compartments: total bone mass, fat mass and lean body mass, the sum of the 
three giving the total body weight, and the determination of regional quantities of these 
components. DXA-estimated appendicular lean mass (ALM) - which comprises muscle and 
other components such as skin, tendons, connective tissues, and the lean portion of adipose 
tissue - was used to calculate total body skeletal muscle mass (SM) according to the 
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prediction model developed by Kim et al 19 using the formula: Total-body SM = (1.13 x 
ALM) – (0.02 x age) +0.97. This prediction model has been derived from a large healthy 
adult population of men and women, aged 18 to 88 y, mean 49 ± 19 for women, with a 
BMI<35, mean 24.8 ± 4.3 for women. Quality control for dual energy x-ray absorptiometry, 
including calibration, was performed every day, using the standard provided by the 
manufacturer. 
Fat mass and lean mass percentages were calculated dividing total fat or lean mass (kg) by 
body weight (kg) multiplied by 100.  
 
Muscle strength 
 
Isometric grip strength was measured using an adjustable hand-held dynamometer 
(JAMAR dynamometer) at the non-dominant hand. Each test was done in triplicate, and the 
average was used in the analysis 20. Leg (or knee) extensor strength was measured using the 
Hoggan MicroFET hand-held dynamometer. To obtain one main outcome measurement for 
lee extensor strength, maximum leg extensor strength was defined as the maximum strength 
for the right or the left leg, whichever was largest, in a position of 120-degree extension. 
Statistical analyses were based on the physical unit momentum [Newton meters (Nm)], 
obtained by multiplying the maximum strength (in N) and the distance of the dynamometer to 
the knee joint (in meters). 
 
Parameters of functional ability 
 
1- Physical performance score 
 
Lower extremity function, or physical performance, was measured as described by 
Guralnik et al.21, and included measurement of standing balance, walking speed, and ability to 
rise from a chair. Three tests of standing balance were considered as hierarchical in difficulty 
in assigning a single score of 0 – 4 for standing balance. For the 8-ft walk and repeated chair 
stands, those who could not complete the task were assigned a score of 0. Those completing 
the task were assigned scores of 1– 4, corresponding to the quartiles of time needed to 
complete the task in this population, with the fasted times scoring as 4. A summary 
performance scale was created by summing the category scores for the walking, chair stand, 
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and balance tests, yielding possible sum scores between 0 and 12. Impaired physical 
performance was defined as a score under 7; impaired standing balance was defined as a score 
< 4 and impaired chair standing and walking speed were defined as a score ≤ 1. 
 
2- Physical activity 
 
The questionnaire on mobility in the elderly developed and validated by L.E. Voorrips et al 
22
 was used to assess physical activity. It includes three items of physical activities during the 
preceding year: scores in household activities, sporting activities, and other physically active 
leisure time activities. Household activities concern 10 questions and are ranging from very 
active to inactive. Sport and other activities were asked for in terms of type of activity and 
hours per week, and month per year spent on it. A classification was done using an intensity 
code based on net energetic costs of activities according to work posture and movements. The 
three parts together yield a total physical activity score 22, for which there is no maximum by 
design.  
 
3- Activities of daily living 
 
Information on the participant’s satisfaction with performing activities of daily living was 
obtained by a trained research assistant using the Stanford Health Assessment Questionnaire. 
The disability index was composed of the mean score (0 indicating no impairment, 3 unable 
to perform) for six component questions on arising, walking, bending, and getting in and out 
of a car 23. This score potentially ranges from 0-3 (maximum sum of 18 divided by 6 
components), the higher the worse. Impairment in activities of daily living was defined as a 
score > 0 on the Health Assessment Questionnaire. This does not imply total impairment, 
such as wheel chair dependency, as women had to be able to come to our department. 
 
Data analysis 
 
Body composition data were not available for 6 women, leaving 396 women for analyses. 
Distributions of population characteristics, with anthropometrical measures, body 
composition and physical function parameters were expressed as means and standard 
deviations for continuous variables, and frequency and percentage for categorical variables. 
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Because the distribution of the health assessment questionnaire disability score was skewed, it 
was converted into a dichotomous variable, 0 for no disability, 1 when disabilities were 
present (score > 0). Multivariate regression analysis was used to determine the association 
between body composition and physical function, to adjust for age and BMI, and further 
possible confounders. Linear regression analysis was used for continuous variables, e.g., grip 
and leg extensor strength, physical performance score, and physical activity. Logistic 
regression analysis was used to analyze dichotomous outcomes. Statistical analyses were done 
using SPSS for Windows (version 9.0). 
 
Results 
 
General characteristics of the study population are given in Table 1.  
 
One hundred and seventy three participants were overweight (BMI ≥ 25 kg/m², 43.7%) and 70 
were obese (BMI ≥ 30 kg/m², 17.7%). The following parameters decreased with age: lean 
body mass (-1.5 kg/ 10 yrs, p=0.02), as well as maximal leg extensor muscle strength  (-10.6 
Nm/ 10 yrs, p<0.01) grip strength (-2.7 kg/ 10 yrs, p<0.01), and physical performance score (-
1.16 points/ 10 yrs, p<0.01). Impairment in activities of daily living increased with 10%/ yr 
(p<0.01). BMI, fat mass and hip circumference were not related to age, whereas waist to hip 
ratio significantly increased with age, due to an increase in waist circumference (+3 cm/10 
yrs, p<0.01). Higher fat mass was closely associated with higher lean mass (Pearson 
correlation coefficient r=0.52, p<0.01). Also higher fat mass was associated with higher 
maximum leg extensor strength (r=0.24, p<0.01), while grip strength did not differ (r=-0.02, 
p=0.75).  
 
Relations between fat mass, lean mass, and muscle strength 
 
An increase in lean mass was significantly associated with higher grip and leg muscle 
strength. Higher fat mass was associated with a non-significant decrease in grip strength, and 
with a higher leg muscle strength (Table 2).  
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After adjustment for lean mass, the decrease in grip strength with higher fat mass became 
significant, and the relation with muscle strength of the knee was lost suggesting an increase 
in leg strength due to the higher total mass that had to be carried. Lean/fat ratio and lean mass 
percentage were inversely associated with maximum leg extensor strength, which may again 
be explained by an effect of weight itself on leg muscle strength. Indeed, this negative relation 
was not observed for grip strength. 
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The relation between fat mass and lean mass in individuals with increasing BMI is shown in 
Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Proportions of fat mass (○ open circles) and lean mass (● closed circles) with 
increasing BMI. 
 
Increasing BMI was predominantly due to increase of fat mass, which went together with a 
much lower increase of lean mass. Although there was no absolute decline of lean mass 
observed with increasing fat mass, lean mass relative to fat mass (lean/fat ratio) sharply 
decreased with increasing BMI (ß = -0.116 ± 0.005; p<0.001) (Figure 2). For BMI values 
under 27, lean mass represented more then twice the fat mass in weight. For BMI values 
above 27, the proportion decreased and tended to equality (Figure 2).  
 
Figure 2. Lean/fat ratio values with increasing BMI 
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Relations between fat mass, lean mass, muscle strength and functional 
ability (physical performance score, physical activity and impaired 
activities of daily living) 
 
Twenty four percent of the participants had a decreased activities of daily living function 
(n=96), but as expected due to the inclusion criteria used, no participant showed severe 
disability (Health Assessment Score = 3, Figure 3). 
 
Figure 3. Distribution of disability in activities of daily living. 
 
10 Kg increase in total fat mass was associated with 0.5 points lower physical performance 
and 1.1 points lower physical activity, and with 64 % higher frequency of impaired activities 
of daily living, demonstrating an strong adverse effect of fat mass which does not seem to be 
compensated by the observed parallel increase in leg muscle mass (Table 3). 
Higher lean mass and total skeletal muscle mass were not significantly associated with 
higher physical performance, physical activity and lower frequency of impaired activities of 
daily living. After adjustment for fat mass, 10 kg increase in total lean mass was associated 
with 2.2 points higher physical activity, and 10 kg increase in total body skeletal muscle mass 
was associated with 1.14 points higher physical performance score, 4.7 points higher physical 
activity and 71 % lower frequency of impaired activities of daily living. 
Grip and leg extensor muscle strength were significantly associated with higher physical 
performance, physical activity and lower frequency of impaired activities of daily living, 
independently of fat mass (Table 3). 
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Discussion  
 
In this group of independently living postmenopausal women younger than 75 years, 
higher lean mass was related to higher muscle strength, and muscle strength was associated 
with better functional ability. However, higher fat mass was significantly related with lower 
functional ability (lower physical performance score, lower physical activity and higher 
frequency of disability). Increased lean mass and muscle strength associated with higher fat 
mass were mainly localized in the legs, most likely due to the higher mass to be carried. This 
increase in lean mass and leg extensor muscle strength was not sufficient to overcome the 
negative effects of fat mass on physical function.  
Before further interpreting these data some issues have to be addressed. In this study, we 
obtained direct body composition measures using DEXA. This allows better insight in the 
respective associations of fat mass and muscle mass with disability. Only about one quarter of 
the participants of this study reported the presence of some chronic diseases (hypertension, 
heart disease, COPD, and diabetes mellitus). The inclusion criteria used excluded participants 
with important limitations in physical performance and physical activities or likely to impede 
daily living activities. No women included in our study had yet developed a state of clear 
frailty or disability, such as wheelchair dependency. The selection of this age group, however, 
was expected to allow the detection of early determinants that are associated with disability 
during the aging process.  
We did not include any test of "fitness" in this study. Some obese women are very fit and 
have increased muscle mass and fat. If included, such individuals may blunt the relationship. 
However, in our study population, there are no obese (BMI >/ 30) women with >70% lean 
mass (as percentage of body weight), and only 14 women with BMI >/ 25 have >70% lean 
mass, which reduces the likelihood that we enrolled very fit obese women. 
The increase in waist to hip ratio with age seen in the individuals studied is consistent with 
redistribution of body fat, and the accumulation of fat mass before age 60 14, 25, which is 
eventually followed by a decrease with older age 26.  
The decrease of lean and skeletal muscle mass with age is consistent with results from both 
cross-sectional and longitudinal studies, which have shown a lean mass peak in the third to 
fourth decade of life, followed by a steady decline with advancing age among healthy elderly 
people 6,26,27.  
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An unanswered question in many studies is how the increase in fat load with age and the 
age-related decrease in lean mass interact in their effects on the functional impairment 
developing during the aging process. Being overweight impairs physical activity in all age 
groups: the increased prevalence of functional limitations and disability with increasing BMI 
has been widely reported, while the relative increase in muscle mass with increasing BMI 
might explain some of the discrepant results in previous studies between men and women 
9,10,15,28
. Epidemiological studies have shown that the prevalence of being overweight climbs 
in women from age 20 to 60 and particularly increases among non-hispanic white women in 
their 50’s 29. The factors implied in this weight gain among mid-aged women are probably 
modifiable and include behavior and life-style. Longitudinal studies in elderly individuals 
indicate that lean mass remains stable when fat mass increases, decreases slightly in weight 
stable subjects, and decreases sharply in elderly people that lose weight, despite normal to 
high levels of recreational and sport activities 30.  
It is probable that at this age group of healthy independent living women, fat mass is a 
more important determinant of disability, while sarcopenia becomes important as a 
determinant much later in the aging process.  
Unequivocal conclusions are limited by the fact that the different compartments of body 
composition have different relationship to morbidity, disability, and health status. Loss of 
muscle is in the aging process initially replaced by fat. DXA- scan does not allow to make this 
discrimination. Therefore it remains often difficult to conclude which factor in the 
interrelation between the changes in fat mass and muscle mass plays the overriding role in 
disability among older people.  
In this study in healthy independent living women younger than 75 years, fat mass appears 
to be a major risk marker for physical functional status and disability. An increase in fat mass 
and body weight leads to a compensatory increase in the muscle mass and muscle strength of 
the legs, which, however, only partially prevents the decrease in physical function and activity 
and the development of disability. However, due to the cross-sectional nature of the study, 
causal inference is limited, and future studies with prospective designs should further explore 
our findings. 
These observations might indicate a different approach to the prevention of disability in 
this age group of elderly women, than is currently considered for the oldest old (>75 years) 
where the role of sarcopenia in the disability seems much more outspoken.  
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The relationship between estrogens, other hormones and 
physical functional status in healthy postmenopausal women 
 
 
 
Abstract 
Objective: The aim of this study was to investigate whether serum levels of circulating hormones, 
in particular estrogen concentrations, are associated with functional ability in healthy postmenopausal 
women younger than 75 years of age.  
Method: We performed a cross-sectional study among 402 healthy postmenopausal women, aged 
56-73 years, randomly selected between 8 and 30 years after menopause. Serum concentrations of 
estradiol (E2), estrone (E1), and sex hormone-binding globulin (SHBG), testosterone (T), IGF-1, 
DHEA and DHEAS, and insulin were measured by immunoassay. Body composition measures 
included bone mineral density (BMD), lean mass and fat mass assessed by dual-energy x-ray 
absorptiometry. Functional ability was estimated by measuring muscle strength (grip and leg 
extension) using dynamometry, and physical performance (PPS), and by assessing the number of 
problems in activities of daily living (impaired ADL or disability).  
Results: Higher fat mass was associated with a lower PPS and higher disability. Higher lean mass 
was associated with lower disability on basis of muscle strength. A higher lean mass, muscle strength, 
and fat mass were also independently associated with a higher BMD. Estrogen levels were positively 
related to BMD, and high estrogen levels were negatively correlated with ability. T had small effects 
on BMD, which were lost after adjustment for E2, and was negatively correlated with PPS 
independent of E2 levels, and lean and fat mass. After adjustment for BMI, SHBG was negatively 
associated with BMD and leg muscle strength, independent of insulin. Insulin showed positive 
associations with lean, fat and bone mass, and IGF-1 was positively related to leg muscle strength, 
physical performance and a negatively to disability.  
Conclusion: In this population of relatively healthy postmenopausal women, fat mass was the 
major factor negatively affecting ability. Estrogens, T and SHBG levels were related to BMD and fat 
mass. Known positive effects of IGF-1 on muscle strength and activity of daily living were confirmed. 
The remaining estrogen levels in the postmenopausal state do not exert positive effects on lean mass, 
muscle strength or physical performance. Activities of daily living were even negatively related to E2 
in those women with the highest BMI. Unexpectedly and unexplained, T was a negatively associated 
with physical performance. 
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Introduction 
 
Aging is known to induce profound changes in body composition, particularly an 
accumulation and redistribution of body fat and a decrease of skeletal muscle mass. However, 
since declining muscle mass explains loss of strength only partially, other yet undetermined 
factors have to play a role in the loss of strength seen with aging 1. Sex hormones are known 
to be important determinants of body composition, but less is known about their role within 
the aging process. There is evidence that the age-related changes in body composition, 
together with the age-associated somatopause, are related to declining levels of serum 
testosterone (T) in men 2. In women, menopausal transition and early postmenopausal status 
are associated with a selective increase in intra-abdominal fat independently of age and total 
adiposity 3,4. The remaining circulating levels of sex hormones are also known to play an 
important physiological role in bone metabolism after the menopause 5-7, with evidence that 
estradiol levels under a given threshold are strongly associated with rapid bone loss 7. In 
addition, sex hormone binding globulin (SHBG), which determines free levels of sex steroids, 
may affect postmenopausal estrogen physiology substantially. Investigation of hormonal 
factors associated with the decline in muscle mass and strength, and the development of age-
related disability is important in the light of the probably increasing proportion of older 
persons expected over the next decennia. 
The aim of this study in healthy postmenopausal women younger than 75 years was to 
investigate the effects of endocrine determinants, particularly estrogens, testosterone and 
SHBG concentrations, on functional abilities. Lean body mass, fat mass and muscle strength 
were measured in order to get better insight in direct or indirect actions of these endocrine 
effects.  
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Subject and methods 
 
Study population 
 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) 8. In 
PROSPECT a total of 17,395 healthy participants who came for breast cancer screening, aged 
49-70 years, living in Utrecht and surroundings, were enrolled between 1993 and 1997. Using 
baseline data from PROSPECT, we selected women who had experienced a natural 
menopause between 8 and 30 years ago. In addition, inclusion criteria were an intact uterus 
and at least one intact ovary, and no use of sex steroids after the reported date of last 
menstruation. Out of 1803 eligible women, 902 women were invited and 553 (61%) answered 
positively. Four hundred and two participants were finally included in our study. Women 
were considered sufficiently healthy to participate when they were physically and mentally 
able to visit the study center independently. Each participant underwent all tests and 
assessments during two visits to the study center. The study was approved by the Institutional 
Review Board of the University Medical Centre, Utrecht, and written informed consent was 
obtained from all participants.  
 
Measurements 
 
Information on health was obtained on basis of medical history, registration of current 
medication and physical examination. Height, weight, waist and hip circumference were 
measured with the subject in standing position wearing indoor clothes and no shoes. Body 
mass index (BMI) was calculated as the weight in kilograms divided by the square of the 
height in meters. 
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Hormone measurements  
 
Venous blood samples were collected in the morning between 8.00 and 11.00 a.m. after an 
overnight fast. Serum was separated by centrifugation and frozen at –80o C. Serum 
concentrations of estradiol (E2, pmol/l), estrone (E1, pmol/l), dehydroepiandrosterone 
(DHEA nmol/l), DHEAS (µmol/l) and testosterone (T, nmol/l) were estimated using  
radioimmunoassay (RIA) kits purchased from Diagnostic Systems Laboratories (Webster, 
TX, USA). Sex hormone binding globulin (SHBG, nmol/l) was measured using a 
chemoluminescence based immunometric assay on the Immulite 2000 system (Diagnostic 
Products Corporation, Los Angeles, CA, USA). 
Total IGF-1 was determined by a IGFBP-blocked RIA in the presence of a large excess of 
IGF-II as described previously9. Insulin was measured by a commercially available RIA 
(Medgenix Diagnostics, Nivelles, Belgium). Intra- and interassay coefficients of variation, 
determined on basis of duplicate results of samples and of results of internal quality control 
serum pools with three different levels of analyse, respectively, were less than 20% for 
oestrone, less than 15% for oestradiol and androstenedione, less than 12% for testosterone and 
DHEA and less than 8% for cortisol, DHEAS and SHBG. 
Non-SHBG-bound T and E2 were calculated using the method described by Sodergard et 
al.10, using a fixed plasma albumin concentration of 40 g/l 11. 
 
Bone mineral density and body composition 
 
Total body bone mineral density and body composition were measured using DXA 
(Hologic QDR1000, Hologic Europe, Zaventem, Belgium). Quality control for dual energy x-
ray absorptiometry, including calibration, was performed every morning, using the standard 
provided by the manufacturer. Total body DXA scan allows the simultaneous determination 
of regional quantities of three distinct compartments: bone mass, fat mass and lean body 
mass, the sum of the them giving the total body weight. 
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Muscle strength 
 
Isometric grip strength was measured using an adjustable hand-held dynamometer 
(JAMAR dynamometer) at the non-dominant hand. Each test was done in triplicate, and the 
average was used in the analysis 12. Leg (or knee) extensor strength (LES) was measured 
using the Hoggan MicroFET hand-held dynamometer. To obtain one main outcome 
measurement for LES, maximum LES (MLES) was defined as the maximum strength for the 
right or the left leg, whichever was largest, in a position of 120-degree extension. Statistical 
analyses were based on the physical unit momentum [Newton meters (Nm)], obtained by 
multiplying the maximum strength (in N) and the distance of the dynamometer to the knee 
joint (in meters). 
 
Physical performance score 
 
Lower extremity function, or physical performance, was measured as described by 
Guralnik et al. 13, and included measurement of standing balance, walking speed, and ability 
to rise from a chair. Three tests of standing balance were considered as hierarchical in 
difficulty in assigning a single score of 0 – 4 for standing balance. For the 8-ft walk and 
repeated chair stands, those who could not complete the task were assigned a score of 0. 
Those completing the task were assigned scores of 1– 4, corresponding to the quartiles of time 
needed to complete the task in this population, with the fastest times scoring as 4. A summary 
performance scale was created by summing the category scores for the walking, chair stand, 
and balance tests, yielding possible sum scores between 0 and 12. Impaired physical 
performance was defined as a score under 7; impaired standing balance was defined as a score 
< 4 and impaired chair standing and walking speed were defined as a score ≤ 1. 
 
Activities of daily living 
 
Information about satisfaction on performing activities of daily living (ADL) was obtained by a 
trained research assistant using the Stanford Health Assessment Questionnaire (HAQ). The disability 
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index (HAQ) was composed of the mean score (0 indicating no impairment, 3 unable to perform) for 
six component questions on arising, walking, bending, and getting in and out of a car 14. This score 
potentially ranges from 0-3 (maximum sum of 18 divided by 6 components), the higher the worse. 
Impairment in activities of daily living was defined as a score > 0 on the Health Assessment 
Questionnaire. This does not imply total impairment, such as wheel chair dependency, as women had 
to be able to come to our department. 
 
Data analysis 
 
Body composition data were not available for 6 women, leaving 396 women for analyses. 
Distributions of population characteristics, with anthropometrical measures, body 
composition and physical function parameters were expressed as means and standard 
deviations for continuous variables, and frequency and percentage for categorical variables. 
Multivariate regression analysis was used to determine the association between determinants 
of functional status and hormones and physical parameters to adjust for age and BMI, and 
further possible confounders. Additional analyses were performed within tertiles of fat mass 
in order to discriminate between cause and effect. Because the distribution of the health 
assessment questionnaire disability score was skewed, it was converted into a dichotomous 
variable, 0 for no disability, 1 when disabilities were present (score > 0). Correlations 
between hormones were assessed by using Pearson’s correlation coefficient r. Statistical 
analyses were done using SPSS for Windows (version 12.0). 
 
Results 
 
General characteristics of the study population including results of hormone measurements 
are given in Table 1.  
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TABLE 1. Characteristics of the study population (n = 396). 
Characteristic Mean (SD) 
Age (year) 66.3 (3.8) 
Time since menopause (year) 17 (6.4) 
Age at menopause (year) 49.6 (4.5) 
Physical characteristics  
Body Mass Index (kg/m²) 26.0 (4.2) 
Physical Performance score (points) 8.97 (1.7) 
Impaired activity of daily living HAQ (points) 0.064 (0.15) 
Total Bone Mineral Density (g/cm²) 1.025 (0.095) 
Total fat mass (kg) 23.5 (8.45) 
Total lean mass (kg) 44.9 (5.0) 
Grip strength (N) 24.8 (4.8) 
Maximum Leg Extensor Strength (Nm) 119.9 (22) 
Hormones  
Estradiol (pmol/l) 19.8 (13) 
Non SHBG bound E2 (pmol/l) 12.44 (9.41) 
Estrone (pmol/l) 44.6 (36.3) 
Testosterone (nmol/l) 1.97 (0.8) 
Non SHBG bound T (nmol/l) 0.89 (0.46) 
Dehydroepiandrostendione (DHEA) (nmol/l) 13.24 (8.1) 
DHEAS (umol/L) 2.25 (1.4) 
SHBG (nmol/l) 59.4 (26.7) 
Insulin (mU/l) 11.8 (7.15) 
Insulin-like growth factor-1 (IGF-1) (nmol/l) 17.9 (7.18) 
 Values are expressed as mean (standard deviation). 
 
Relations between body composition and characteristics of physical 
functional status 
  
BMD, lean body mass, grip strength, leg muscle strength and physical performance 
decreased with age and impaired ADL increased with age, while fat mass and BMI were not 
related to age (Table 2).  
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Table 2: Relations between physical characteristics and age 
 ß coefficient± SE P 
Physical Performance Score (points) -1.16± 0.22 < 0.001 
Disability HAQ (log) 0.40 ± 0.13 0.002 
Total Body BMD  (g/cm²) -0.04 ± 0.01 0.001 
Body Mass Index  (kg/m²) 0.60 ± 0.55 0.277 
Total fat mass (kg) 0.18 ± 1.11 0.913 
Total lean mass (kg) -1.51 ± 0.65 0.021 
Grip force (N) -2.77 ± 0.62 < 0.001 
Max Leg Extension Strength (Nm) -10.64 ± 2.84 < 0.001 
ß coefficient reflects changes in unit per 10 year. For example, PPS decreases 1.16 points per 10 year. 
 
An algorithm representing the observed independent and significant relationships between 
the compartments of body composition and the parameters of functional status is shown in 
Figure 1.  
Higher muscle strength was observed with increasing lean body mass, and participants 
with higher muscle strength scored better in the PPS and had lower impaired ADL. Higher 
lean mass association with lower impaired ADL was lost after adjustment for muscle strength. 
Higher fat mass was significantly and independently associated with a lower PPS, and with a 
higher impaired ADL. Lean mass and fat mass were positively related to each other. Finally, a 
higher lean mass, muscle strength, and fat mass were independently associated with a higher 
BMD. There was no significant relation found between PPS and BMD. 
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Figure 1. Algorithm of mutual correlations between parameters which determine validity 
All adjusted for age and BMI, except for §: Not adjusted for BMI.  Lean mass was adjusted for fat mass. 
***P-value ≤ 0.001. **P-value ≤ 0.01. *P-value ≤ 0.05 
 
 
Mutual relations between hormone levels 
 
High Pearson correlation coefficients were found for the relationships between the 
circulating levels of E2 and E1, between non-SHBG-bound T and non-SHBG-bound E2, and 
between SHBG and non-SHBG-bound E2, non-SHBG-bound T, and insulin. Among the 
adrenal hormones, we further restricted the presentation of the results to T because of the high 
correlations and similarity of results between T, DHEA and DHEAS (Table 3). 
 
+
+
+
-
+
+
+
-
-
+
Lean
body mass
Muscle
strength
Impairment
in Activity of
Daily Living
Bone Mineral
Density
Physical 
Performance Score
Fat mass
2.29 ± 0.22 Nm/kg***(MLES)
0.34 ± 0.05 N/kg***(GripF)
-0.012 ± 0.002 log/Nm***( MLES) 
0.023 ± 0.010 log/N* ( GripF)
0.005 ± 0.001 (gr/cm²)/kg***
0.005 ± 0.001 (gr/cm²)/kg***
0.0045 ± 0.001(gr/cm²)/kg***§
-0.042 ± 0.010 points/kg*** §
0.022 ± 0.006 log/kg** §( HAQ)
-0.21 ± 0.024 log/points***( HAQ)
0.025 ± 0.004 points/Nm***(MLES)
0.058 ± 0.02 points/N**(GripF)
0.0008 ± 0.001 (gr/cm²)/Nm***(MLES)
0.003 ± 0.001 (gr/cm²)/N***(GripF)
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Table 3: Pearson correlation coefficients between hormones levels and bindings proteins 
 
E2 Non 
SHBG 
E2 
E1 T Non 
SHBG  T 
DHE
A 
DHE
AS 
SHB
G 
Ins 
IGF-1 0.03 0.06 0.05 0.13 
** 
0.19 
** 
0.05 0.15 
** 
-
0.17 ** 
0.04 
Insulin 0.12 
** 
0.18 
** 
0.13 
** 
0.02 0.17 
** 
-
0.12 * 
-
0.15 ** 
-
0.30 ** 
- 
SHBG 
-
0.27 ** 
-
0.45 ** 
-
0.24 ** 
-
0.11 * 
-
0.54 ** 
0.11  
* 
-
0.03 
-  
DHEAS 0.32 
** 
0.28 
** 
0.28 
** 
0.35 
** 
0.29 
** 
0.63 
** 
-   
DHEA 0.23 
** 
0.16 
** 
0.17 
** 
0.43 
** 
0.26 
** 
-    
Non 
SHBG  T 
0.48 
** 
0.57 
** 
0.41 
** 
0.85 
** 
-     
T 0.40 
** 
0.38  
** 
0.35 
** 
-      
E1 0.62 
** 
0.63 
** 
-       
Non 
SHBG 
E2 
0.96 
** 
-        
Pearson correlation coefficient. ** P-value <0.01, * P-value <0.05 
 
Relations between hormone levels and physical characteristics 
 
The associations between hormone levels and age and BMI are shown in Table 4.  
 
Table 4:  Relation between hormones and age or BMI 
 Age 
ß coefficient ± SE 
P BMI 
ß coefficient ± SE 
P 
Estradiol (pmol/l) -0.31 ± 1.70 0.856 0.94 ± 0.148 < 0.001 
Non-SHBG bound E2 (pmol/l) -0.01 ± 1.23 0.991 0.83 ± 0.104 < 0.001 
Estrone  (pmol/l) 6.50 ± 4.75 0.173 2.32 ± 0.417 < 0.001 
Testosterone (nmol/l) 0.16 ± 0.10 0.126 0.020 ± 0.009 0.036 
Non-SHBG bound T (nmol/l) 0.086 ± 0.06 0.156 0.03 ± 0.005 < 0.001 
DHEA (nmol/L) -3.91 ± 1.05 < 0.001 -0.25 ± 0.096 0.011 
DHEAS (umol/L) -0.76 ± 0.18 < 0.001 -0.026 ± 0.016 0.106 
SHBG (nmol/l) -0.83 ± 3.49 0.813 -2.59 ± 0.290 < 0.001 
Insulin (mU/L) 0.105 ± 0.94 0.262 0.610 ± 0.080 < 0.001 
IGF 1 (nmol/L) -1.42 ± 0.94 0.130 -0.092 ± 0.085 0.285 
ß coefficient reflects changes in unit per 10 year and per kg/m² BMI. For example, DHEA decreases 
3.91 nmol/l per 10 years and 0.25 nmol/l per kg/m². 
 
Only DHEA and DHEAS were associated with age, and most hormone levels measured 
were associated to BMI, excepted for DHEAS, and IGF-1. 
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1- Estrogen 
Associations of non-SHBG bound E2 levels with measured physical parameters were 
stronger than for estradiol levels (Table 5). Non-SHBG bound E2 was positively related to fat 
mass, lean mass, BMD, leg strength and disability, and was negatively related to PPS. After 
adjustment for BMI only the relations with BMD and disability remained significant (Table 
5). Similar results were obtained with E2 and E1 consistent with the high correlation between 
levels of both hormones. After adjustment for BMI, all E1 relations were lost (results not 
shown). 
 
Table 5:  Relation between hormones and physical parameters 
 
Fat 
Mass(kg) 
β±SE 
Lean 
mass(kg) 
β±SE 
BMD 
(gr/cm²) 
β±SE 
MLES 
(Nm) 
β±SE 
GripF (N) 
 
β±SE 
PPS 
(points) 
β±SE 
Impaired 
ADL 
(logHAQ) 
β±SE 
E2 pmol/l 0.18± 
0.03** 
0.045± 
0.02* 
0.0016± 
0.0004** 
0.11± 0.085 0.002± 0.02 -0.024± 
0.008** 
0.012± 
0.004** 
Non SHBG 
bound E2 
pmol/l 
0.30± 
0.04** 
0.09± 
0.03** 
0.003± 
0.0005** 
0.26± 0.12* -0.01± 0.03 -0.04± 
0.01** 
0.02± 
0.005** 
Non SHBG 
bound E2 
pmol/l (BMI) 
- -0.026± 
0.024  
0.001± 
0.0005* 
0.08± 0.12 -0.002± 0.03 -0.020± 
0.011 
0.012± 
0.006* 
T nmol/l 0.786± 
0.535 
0.349± 
0.318 
0.017± 
0.006** 
-1.97 ± 1.40 0.096± 0.31 -0.41± 
0.11** 
0.089± 
0.064 
Non SHBG 
bound T nmol/l 
4.14± 0.9** 1.77± 
0.54** 
0.05± 
0.01** 
1.8 ± 2.4 -0.31± 0.53 -0.84± 
0.21** 
0.23± 0.11* 
Non SHBG 
bound T nmol/l 
(BMI) 
- 0.04± 0.48 0.03± 
0.01** 
-1.34 ± 2.45 -0.23± 0.55 -0.60± 
0.22** 
0.13± 0.11 
SHBG nmol/l -0.11± 
0.015** 
-0.045± 
0.009** 
-0.0009± 
0.0002** 
-0.151± 
0.040** 
0.004± 
0.009 
0.008± 
0.003* 
-0.003± 
0.002 
SHBG nmol/l 
(ins) 
-0.08± 
0.016** 
-0.04 ± 
0.010** 
-0.001 ± 
0.0002** 
-0.15 ± 
0.044** 
0.001± 0.01 0.007 ± 
0.004 
-0.002± 
0.002 
SHBG nmol/l 
(BMI) 
- -0.003 ± 
0.009 
-0.0004 ± 
0.0002* 
-0.09 ± 
0.044* 
0.002± 0.01 0.004 ± 
0.004 
-0.0006± 
0.002 
Insulin mU/l  0.40± 
0.057** 
0.183± 
0.034** 
0.002± 
0.001** 
-0.22± 0.156 0.016± 
0.034 
-0.04± 
0.012* 
0.021± 
0.007** 
Insulin mU/l 
(SHBG) 
0.31± 
0.057** 
0.14± 
0.035** 
0.002± 
0.001* 
0.06± 0.16 0.017± 
0.036 
-0.041± 
0.016** 
0.019± 
0.007* 
Insulin mU/l 
(BMI) 
- 0.05 ± 0.032 0.0007± 
0.001 
-0.026± 
0.164 
0.03± 0.04 -0.023± 
0.013 
0.014± 
0.008 
IGF-1 nmol/l -0.11± 0.06 0.034± 
0.035 
0.001± 
0.001 
0.36± 0.15* -0.008± 
0.034 
0.029± 
0.014* 
-0.015± 
0.007* 
β coefficient reflects changes in unit physical parameters per unit hormone concentration. 
(BMI) Adjusted for BMI. (ins) Adjusted for insulin. (age) Adjusted for age. (SHBG)  Adjusted for SHBG 
**p≤0.005 * p≤0.05 
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2- Testosterone 
While Testosterone was positively associated with BMD and negatively related to PPS, 
non SHBG bound T was positively related to fat mass, lean mass, BMD and disability. T was 
negatively related with PPS. After adjustment for BMI the relations with disability and lean 
mass were lost, and the relation with BMD was lost after adjustment for E2. The negative 
relation of T with PPS was independent of E2, or BMI. 
 
3- SHBG 
Serum SHBG concentrations were inversely related to fat mass, lean body mass, BMD, 
and MLES and positively related to PPS. After adjustment for BMI or fat mass, only the 
association with BMD and MLES remained significant. The relation between SHBG and 
muscle strength was lost after adjustment for lean mass. Adjustment for insulin did not alter 
these relations. 
 
4- Insulin and IGF-1 
Insulin was positively associated with fat mass, lean mass and impaired ADL and was 
negatively associated with PPS. All those relations were lost after adjustment for BMI, while 
adjustment for SHBG did not materially alter these relations. 
IGF-1 was positively related to MLES and PPS, and negatively associated with disability.  
Further analyses on the unexpected relationships between E2 and ADL and T and PPS 
were performed within tertiles of fat mass (data not shown). The relation of E2 with disability 
was found only in the highest tertile, suggesting a causal role of fat mass. The relation of T 
with PPS was found in the lowest tertile, which confirms that the T effect is independent of 
fat mass, and the relation was independent of fat mass, SHBG and insulin. E2, DHEA and 
DHEAS did not  demonstrated the same relationships. 
A summary of these hormonal effects in the algorithm in figure 1 is shown in Figure 2.  
 
 
 
 
Chapter 6 
  114 
+
+
+
-
+
+
+
-
-
+
Insulin
Insulin
E1, E2
E2, (T)
IGF-1
SHBG
IGF-1
SHBG
T
T
E2
    
+ relation
- relation
Lean
body mass
Muscle
strength
Bone Mineral
Density
Physical 
Performance Score
Impairment
in Activity of
Daily Living
Fat mass
IGF-1
Figure. 2 Independent significant relations between hormone levels and physical 
parameters 
 
Discussion 
 
In this cross sectional study among healthy, independently living women younger than 75 
years, the significant and independent relations between body composition, muscle strength, 
PPS and impaired ADL could be presented in an algorithm which demonstrated a direct 
negative effect of muscle strength and PPS on disability, an indirect negative effect of lean 
mass through muscle strength, and a direct positive effect of fat mass on disability. Lean mass 
and fat mass were positively related to each other. Lean mass, fat mass and muscle strength 
had all three direct independent effects on BMD. 
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The role of hormones measured varied considerably. Besides the strong effect of estrogens 
on BMD, this study did not demonstrate any effects of estrogens on muscle mass, muscle 
strength and physical performance, while high estrogen levels even negatively affect ability. 
Hormone levels of adrenal androgens (DHEA, DHEAS) and T, which is presumably mainly 
produced from adrenal precursors, demonstrated small effects on bone mineral density, lost 
after adjustment for E2, indicating that the effect is caused through aromatization of T to E2. 
T had independent negative effects on PPS which were in particular independent of E2 levels, 
SHBG, lean mass or fat mass. After adjustment for BMI, SHBG was negatively associated 
with BMD and leg muscle strength, independently of insulin. Insulin showed positive effects 
on lean, fat and bone mass, and IGF-1 had positive effects on leg muscle strength, physical 
performance and negative effect on disability.  
Before interpreting these data, some issues need to be addressed. In this study a relatively 
healthy group of independently living women was studied and individuals with clear 
disability were excluded at the start of the study. The presence of disability was 
predominantly related to overweight. The lack of direct relation between lean mass and 
disability is most likely due to this selection. We have shown in an earlier study in this 
population how lean and fat mass were related to each other 15. Lean/fat ratio sharply 
decreased with increasing BMI due to increasing fat mass accompanied by a much lower 
increase of lean mass principally located at the legs. 
The strong relationship of estrogen levels with BMD can be explained by the direct effect 
of E2 on bone metabolism 16-18, with the additional effect of increased fat mass resulting in 
higher mechanical load and higher E2 levels 19,20. The most probable explanation for the 
positive relation between E2 and disability is the role of overweight, confirmed by the 
presence of this relation in the highest fat mass tertile only.  
A study among older men has shown an algorithm where significant relations were found 
between PPS and BMD 21. In our population this relation was absent. A probable explanation 
is the strong effect of fat mass on BMD through mechanical force with increase of 
aromatization in addition to the negative effect of fat mass on PPS. The relationship between 
PPS and BMD seemed masked because when we put BMI, estradiol and PPS in the same 
model, the positive association of PPS with total body BMD became significant.  
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In this population of postmenopausal women with low androgen levels, we observed an 
unexplained negative relation between T and physical performance. This relationship seems 
due to a unknown confounder, since it was independent of fat mass, lean mass, SHBG, and 
insulin.  
Although high levels of E2 are known to increase hepatic SHBG synthesis 22, SHBG was 
negatively related with E2 in the present study. This negative relation is probably due to the 
predominant negative relation of SHBG with fat mass in this population: a higher fat mass is 
associated with a higher E2 and a lower SHBG. When adjustment for fat mass was 
performed, both hormones were positively but not significantly associated. 
It is also known that insulin suppresses the liver SHBG synthesis 23-25. Interestingly, the 
effects of SHBG were independent of insulin in our population. In particular, when put 
together in the same linear regression model, both hormones were independently and 
significantly related to fat mass. 
In this population of healthy postmenopausal women without marked disability, fat mass 
negatively affected physical performance and exerted a major role in the presence of 
disability. Estrogens, T and SHBG levels were related to BMD and fat mass. Known effects 
IGF-1 on muscle strength and activity of daily living were confirmed. The remaining estrogen 
levels in the postmenopausal state do not exert positive effects on lean mass, muscle strength 
or physical performance. Activities of daily living were even negatively related to E2 in those 
women with the highest BMI. Unexpectedly and unexplained, T exerted a negative effect on 
physical performance. 
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Relations between body composition, 
functional and hormonal parameters and 
quality of life in healthy postmenopausal 
women  
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Abstract 
Objective: To investigate whether body composition, functional status and serum hormone levels 
are associated with quality of life in healthy postmenopausal women. 
Design: A cross-sectional study among 402 women aged 56-73 years, 8 to 30 years 
postmenopausal. Quality of life (QoL) was assessed using the questionnaire on life satisfaction (QLS), 
with two modules directed at general factors (QLS-General) and health factors (QLS-Health). Muscle 
strength was measured using dynamometry. Functional ability was estimated by physical performance 
(PPS), physical activity during the preceding year, and impairment in activities of daily living (ADL). 
Bone mineral density, lean mass and fat mass were assessed by dual-energy x-ray absorptiometry. 
Fasting levels of serum oestradiol, oestrone, and sex hormone-binding globulin (SHBG), testosterone, 
cortisol, androstenedione, DHEA and DHEAS, Insulin-like Growth Factor (IGF-1), its binding 
proteins (IGFBP –1 and –3) and insulin, were determined.  
Results: Both QLS modules did not decrease with age. The major positive predictor of QLS-
general module was the presence of a partner. Higher physical performance and higher educational 
level of participants’ partners were significantly related to higher QLS-general, while smoking and 
presence of co-morbidities were significantly associated with a lower QLS-general. The determinants 
studied were mostly related to the QLS-health module, the major negative predictor of QLS-health 
being the presence of co-morbidities, followed by physical activity, physical performance and grip 
strength. Higher educational level of participants was related with higher QLS-health module, while 
higher BMI, fat mass and presence of disability were associated with significantly lower QLS-health. 
No consistent relation was found between serum levels of hormones measured and both QLS modules. 
Conclusions: The most important and specific determinant for psychological well being was 
having a partner. Physical and psychological well being are further strongly associated in this 
population of healthy postmenopausal women below 75 years of age, while increasing fat mass was 
related to decreased well being. Our results suggest that in elderly and late postmenopausal women 
hormonal factors do not predict quality of life. 
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Introduction  
 
As the number of postmenopausal women in our society is increasing, the importance of 
the prevention of frailty in these women is increasing together with the growing demand for 
an active old age and for interventions improving the quality of life. In addition to 
menopausal oestrogen deficiency, older age is associated with a decreased hormonal 
production of growth hormone and IGF-1, changes in body composition with osteopaenia, 
sarcopaenia, and fat redistribution,1 and to lower physical activity and muscle strength.2-4 
Different definitions of successful aging, a concept dependent on individual perspectives and 
value systems, have been proposed.5,6 The model of successful aging proposed by Rowe and 
Kahn in which the combination of absence of disease, maintenance of functional capacities, 
and active engagement with life are fundamental,7 can be assessed by means of different 
instruments and questionnaires making it more practical. Based on this model, we 
investigated the interrelationships between serum levels of hormones, body composition, 
physical function parameters and quality of life in a population of postmenopausal women 
between 55 and 75 years, i.e. before old age and overt physical frailty.  
 
Material and methods 
 
Subjects 
 
Participants were recruited from the PROSPECT study, one of the two Dutch cohorts 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC).8 In 
PROSPECT a total of 17,395 healthy participants who came for breast cancer screening, aged 
49-70 years, living in Utrecht and surroundings, were enrolled between 1993 and 1997. Using 
baseline data from PROSPECT, we selected women who had experienced a natural 
menopause between 8 and 30 years ago. In addition, women should have an intact uterus and 
at least one intact ovary and should not have used sex steroids after the reported date of last 
menstruation. Out of 1803 eligible women, a random sample of 902 women were invited and 
553 (61%) answered positively. 402 participants were finally included in our study. Women 
were considered sufficiently healthy to participate when they were physically and mentally 
able to visit the study centre independently. None of the women had obvious cognitive 
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impairment. Each participant underwent all tests and assessments during two visits to the 
study centre. The study was approved by the Institutional Review Board of the University 
Medical Center Utrecht and written informed consent was obtained from all participants. 
 
Measurements 
 
Information on health status was obtained by medical history, registration of current 
medication and physical examination. Height, weight, waist and hip circumference were 
measured with the subject in standing position wearing indoor clothes and no shoes. Body 
mass index (BMI) was calculated as the weight in kilograms divided by the square of the 
height in meters. Information on educational level of participants and their partners was 
available out of the baseline data of PROSPECT. Co-morbidity was defined as the presence 
of one or more chronic conditions based on medication use and self-reported physician 
diagnosis of cardiovascular disease, stroke, diabetes mellitus, COPD, and severe 
osteoarthritis. 
 
Quality of life  
 
Psychological well being or quality of life was assessed using the standardized 
multidimensional questionnaire of life satisfaction from Henrich and Herschbach,9 where 
subjective QoL is reflected by weighting the response to each item for its importance to the 
respondent. The questionnaire of life satisfaction (QLS) used consists of two modules 
covering general quality of life and health, and is easy to complete in less than 20 minutes. 
The first module addresses 8 general dimensions of life satisfaction (QLS-general): 
friends/acquaintances, leisure time/hobbies, general health, income/financial security, 
occupation/work, housing/living conditions, family life/children and partner 
relationship/sexuality. The module QLS-general correlates best with scales assessing 
psychological well being.9 The second module consists of 8 questions regarding general 
health (QLS-health): physical condition/fitness, ability to relax, energy/zest for life, mobility, 
vision and hearing, freedom from anxiety, freedom from aches and pain, and independence 
from help/care. Individual weighing of the items was realized as follows: for each module’s 
item, subjects were first asked to rate the subjective importance of the given area of life; then 
they were asked about the degree of satisfaction in that area. All items are evaluated on a 5-
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point scale, ranging from 0 to 4, with the highest score indicating respectively extremely 
important and very satisfied. We calculated the combination of importance (I) and satisfaction 
(S), for each item ((I-1) x [(Sx2)-5]) according to Herschbach,10 and the sum was calculated 
for each module. Scores on the two modules can vary between –192 and 160. The 
questionnaire produces total scores for each module separately. 
 
Biochemical assessments 
 
Venous blood samples were collected in the morning between 8.00 and 11.00 a.m. after an 
overnight fast. Serum was separated by centrifugation and frozen at –80o C. Serum 
concentrations of oestradiol (E2, nmol/l), oestrone (E1, nmol/l), DHEA (nmol/l) and DHEAS 
(µmol/l) and total testosterone (T, nmol/l) were estimated using  radioimmunoassay kits 
purchased from Diagnostic Systems Laboratories (Webster, TX, USA). Sex hormone binding 
globulin (SHBG, nmol/l) was measured using a chemoluminescence immunometric assay on 
the Immulite 2000 system (Diagnostic Products Corporation, Los Angeles, CA, USA). 
Total IGF-1 was determined by a IGFBP-blocked RIA in the presence of large excess of 
IGF-II as described previously.11 IGFBP-1 and IGFBP-3 were measured with in-house RIAs 
as described previously. Insulin was measured by a commercially available RIA (Medgenix 
Diagnostics, Nivelles, Belgium). Intra- and interassay coefficients of variation, determined on 
basis of duplicate results of samples and of results of internal quality control serum pools with 
three different levels of analyse, respectively, were less than 20% for oestrone, less than 15% 
for oestradiol and androstenedione, less than 12% for testosterone and DHEA and less than 
8% for cortisol, DHEA sulphate and SHBG. 
 
Body composition 
 
Body composition was assessed using dual energy x-ray absorptiometry (DXA) (Hologic 
QDR1000, Hologic Europe, Zaventem, Belgium). This allows the simultaneous measure of 
three distinct compartments: total bone mass, fat mass and lean body mass, the sum of the 
three giving the total body weight, and the determination of regional quantities of these 
components. Quality control for dual energy x-ray absorptiometry, including calibration, was 
performed every morning, using the standard provided by the manufacturer. 
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Parameters of functional ability 
 
1- Muscle strength 
 
Isometric grip strength was measured using an adjustable hand-held dynamometer 
(JAMAR dynamometer, Memphis, TN) at the non-dominant hand. Each test was done in 
triplicate, and the average was used in the analysis.12 Leg (or knee) extensor strength (LES) 
was measured using the MicroFET hand-held dynamometer (Hoggan Health industries, 
Draper, Utah, USA). To obtain one main outcome measurement for LES, maximum LES 
(MLES) was defined as the maximum strength for the right or the left leg, whichever was 
largest, in a position of 120-degree extension. Statistical analyses were based on the physical 
unit momentum [Newton meters (Nm)], obtained by multiplying the maximum strength (in 
N) and the distance of the dynamometer to the knee joint (in meters). 
 
2- Physical performance score 
 
Lower extremity function, or physical performance, was measured as described by 
Guralnik et al.,13 including measurement of standing balance, walking speed, and ability to 
rise from a chair. Three tests of standing balance were considered as hierarchical in difficulty 
in assigning a single score of 0 – 4 for standing balance. For the 2.4 meter walk and repeated 
chair stands, those who could not complete the task were assigned a score of 0. Those 
completing the task were assigned scores of 1– 4, corresponding to the quartiles of time 
needed to complete the task in this population, with the fasted times scoring as 4. A summary 
performance scale was created by summing the category scores for the walking, chair stand, 
and balance tests. Impaired physical performance was defined as a score under 7; impaired 
standing balance was defined as a score < 4 and impaired chair standing and walking speed 
were defined as a score ≤ 1. 
 
3- Physical activity 
 
The questionnaire on mobility in elderly developed and validated by Voorrips et al.14 was 
used to assess physical activity. It includes three items of physical activities during the 
preceding year: scores in household activities, sporting activities, and other physically active 
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leisure time activities. Household activities concern 10 questions and are ranging from very 
active to inactive. Sport and other activities were asked for as type of activity, hours per week 
and month per year spent on it. A classification was done using an intensity code based on net 
energetic costs of activities according to work posture and movements. The three parts 
together yield a total physical activity score.  
 
4- Activities of daily living 
 
Information on the participant’s satisfaction with performing activities of daily living was 
obtained by a trained research assistant using the Stanford Health Assessment Questionnaire 
(HAQ). The disability index (HAQ) was composed of the mean score (0 indicating no 
impairment, 3 unable to perform) for six component questions on arising, walking, bending, 
and getting in and out of a car.15 Impairment in ADL was defined as a HAQ score above 0. 
 
Data analysis 
 
Population characteristics including anthropometrical measures, body composition and 
physical function parameters, quality of life modules and serum hormones levels were 
expressed as the mean and SD, unless otherwise stated. Because distributions of the HAQ 
disability score was skewed, it was converted into dichotomous variables, 0 for no disability, 
1 when disabilities were present (HAQ score > 0). Multiple linear regression analysis was 
used to determine the association between body composition, physical function, serum 
hormone levels on the one hand, and quality of life modules on the other and was also used to 
adjust and control for possible confounders. The change in the R squared statistic produced by 
adding an independent variable was used to estimate the importance of predictor of both QLS 
modules. Statistical analyses were done using the SPSS 12.0 statistical package for Windows. 
 
Results 
 
General characteristics of the study population are given in Table 1.  
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Educational level of participants and their partners (Table 2) shows a similar distribution as 
the total cohort of the prospect-EPIC study where they have been selected.8  
 
 
Relations between physical characteristics and QLS-modules are described in Table 3.  
None of the QLS scores was decreasing with age and they were not related with age at 
menopause or time since menopause. 
 
QLS-general 
 
Partners education level but not participants’ one was significantly associated with higher QLS-
general score (P<0.001) (Table 3), and was the most important predictor of QLS-general (Table 4).  
In decreasing order of R squared values, higher physical performance score was associated 
with 1.5 points higher QLS-general (P=0.01), smoking was associated with 4 points lower 
QLS-general score (P=0.02), and the presence of co-morbidities was associated with 6 points 
lower QLS-general score (P=0.03). Presence of disability was related to 5 points lower QLS-
general (P=0.04), but was dependent on fat mass and co-morbidities.  
None of the twelve circulating hormone levels measured was related to QLS-general score 
(data not shown). 
 
QLS-health 
 
Presence of co-morbidities was significantly associated with lower QLS-health (p<0.01) 
(Table 3), with a R squared value explaining an important part of the variation (Table 4). 
Higher education level of participants but not of their partners was significantly associated 
with higher QLS-health, but with a weak R squared change value. The following associations 
are given in decreasing value of R squared change. 
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1- Parameters of physical function-QLS-health: 
 
Presence of disabilities was related to 20 points lower QLS-Health independent of fat mass 
and chronic disease (P<0.01). One point higher physical activity was related to 0.9 point 
higher QLS-Health score independently of fat mass and chronic disease (P<0.01). Higher 
physical performance was related with 2.7 points higher QLS-health (P<0.01), with chair 
standing as the major factor determining these relations. Grip strength was associated with 0.7 
point higher QLS-Health score per N (p=0.02) independently of fat mass. Leg muscle strength 
was related to 0.1 point higher QLS-Health. This relation became significant after adjustment 
for fat mass (P=0.05).  
 
2- Body composition-QLS-health: 
 
Ten kg higher fat mass was related to 3.8 points lower QLS-health (p=0.04), and 
adjustment for chronic disease attenuated this relation. Lean mass was not related to QLS. 
 
3- Circulating hormones levels- QLS-health: 
 
There was a negative relation between oestradiol and QLS-health (p=0.04) (Table 5a)  
which was only seen in the highest quintile of fat mass and oestradiol (table 5b).  
A negative relation between the insulin and both modules of QLS were only present in the 
highest quintile of insulin and were attenuated after adjustment for fat mass (Table 5b and 5c). 
We did not find any consistent relation between serum levels of the other hormones measured 
and QLS-health. 
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Discussion 
 
In this population of healthy postmenopausal relatively women between 55 and 75 years of 
age, quality of life did not decrease with age or age at menopause. Having a partner was the 
most important predictor of QLS-general. A lower physical performance score, smoking, a 
lower educational level of participants’ partners, the presence of chronic diseases, and the 
presence of disability were associated with lower scores on the QLS-General. The 
determinants studied were mostly related to the QLS-health module. QLS-health was mostly 
determined by functional ability represented by impairments in activities of daily living, 
physical activity and physical performance, independently of fat mass and/or the presence of 
chronic diseases. Of the body composition components, BMD and lean mass were not 
associated with QoL and only fat mass was related to lower QLS-health, probably due to the 
higher frequency of chronic disease associated with overweight. None of the hormonal 
parameters measured were found to be related to QLS-health. 
When interpreting our results, some methodological issues should be taken into account. 
There was no validated Dutch version available of published questionnaires especially 
designed for groups of postmenopausal women, like the WHQ,16 and the specific quality of 
life questionnaire for menopause.17 Furthermore, we did not focus on the perimenopause or on 
the menopausal transition in this study. The numerous general and disease-specific quality of 
life questionnaires share the presence of marked inter- and intra-individual differences in the 
perception and evaluation of objective aspects of life or disease.18 We opted for the 
questionnaire of life satisfaction (QLS) recently developed and validated for the Dutch 
population,19,20 which attempts to deal adequately with the problem of the relative importance 
of individual aspects of quality of life. It is based on the view that dimensions with little or 
great importance to an individual cannot contribute with the same weight to the overall 
quality of life score.9 Recent studies with this QLS questionnaire have demonstrated that 
weighing of the individual items for their importance to the respondent is an effective way to 
incorporate the concept of subjectivity of quality of life in this quality of life instrument.21 It 
is highly correlated with other instruments used to assess mainly psychological aspects of 
well-being,22 such as the general well-Being-Schedule GWB,23 the Beck Depression 
inventory-BDI,24 and the general symptomatic index and the scale “depression” of the SCL-
90-R Symptom Checklist.25  
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Age was not associated with quality of life, partly due to the moderate age-related increase 
of co-morbidities in this population of healthy postmenopausal women. However, the absence 
of association between age and quality of life gives a hopeful perspective and legitimates 
efforts spend on improving quality of life at older age. However, due to the cross-sectional 
nature of the study we cannot exclude the possibility that in this population physical condition 
in elderly women is already quite good, resulting in good QoL, so no investments need to be 
made for further improvement of QoL at older age. 
The QLS-General module was strongly determined by the marital status, being without a 
partner affecting negatively the psychological well being of this population, but not the QLS-
health. This can be explained by the fact that these women were not extremely old and the 
healthiness of this selected population, nevertheless having a psychological dissatisfaction 
resulting from the risk of living a more isolated life lacking an important source of love and 
support. 
The QLS-Health module turned out to have the closest relation with the physical 
characteristics measured, consistent with previous observations that this module correlates 
better than the QLS-general module with scales addressing physical problems.9 
Our results are consistent with the previously reported adverse impact of overweight on 
QoL through physical limitations due to overweight or secondary co-morbidities, impaired 
psychological functioning, and altered social functioning.26,27 In our population the presence 
of chronic diseases associated with overweight explained a large part of this relation. This 
agrees with previous prospective data where BMI was shown to be a strong predictor of long-
term risk for mobility disability in older women, which persists even to very old age.28 
There was no significant positive relation between BMD and QoL, probably due to the 
selection of a healthy population. Nevertheless, a negative association between the presence 
of fractures after 50 years of age and QLS-health was present. 
Physical performance and physical activity were related to higher QLS-Health which 
suggests an important role of physical well-being on the quality of life at this age. The strong 
physical functional disability relation with lower QLS-health could be expected because even 
modest physical impairment may limit participation in productive and recreational activities.  
In addition, several problems in activities of daily living as assessed by the Health 
Assessment Questionnaire are strongly associated with low values of all parts of QLS.  
The absence of clear associations between circulating oestradiol levels and QLS modules is 
consistent with findings from previous studies. It has been well established that the positive 
effects of oestrogen substitution on quality of life at the time of menopause appear exclusively 
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due to menopausal symptoms relieve such as night sweating and hot flushes,29 and no other 
effect of oestrogen on quality of life has been demonstrated.30 However, we cannot exclude 
the possibility that adjustment for fat mass in fact was overadjustment, due to the fact that the 
fat mass is the tissue where conversion of androgens to extrogens primarily takes place in the 
postmenopause. Furthermore, the significant modification of quality of life perception during 
the peri/postmenopausal period seems to depend less upon biology than on socio-economic 
circumstances, individual experiences, resources and cultural morals.31 Several studies have 
reported that oestrogens or combination of androgen and oestrogen replacement therapy of 
postmenopausal women improve wellbeing while providing beneficial effects on bone, lipids, 
sexual functioning, and quality of life,32-35 but these effects are not perceptible in the ranges of 
circulating endogenous hormone levels. 
Our findings are consistent with previous studies where a higher level of physical activity 
in the obese female population was positively associated with health related QoL.36 Whether a 
good quality of life is a consequence or a cause of an overall good physical functional status 
cannot be established because of the cross-sectional nature of this study. 
 
In conclusion, age itself is not associated with decrease in well being, and apart from the 
strong adverse psychological effect of being without a partner, this study suggests that 
physical and psychological well-being are strongly associated in healthy elderly and late 
postmenopausal women younger than 75 years of age. Our results do not support the presence 
of hormonal factors as predictors of quality of life in this age group. The data indicate an 
adverse effect of fat mass on overall well being. 
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The main objective of the studies among postmenopausal women described in this thesis 
was to provide epidemiologic insight in factors associated with successful aging, such as 
avoidance of disability, maintenance of high physical and cognitive function, and sustained 
engagement in social activities. We investigated the associations between endogenous 
hormone levels and parameters of successful aging. For this purpose, a combination of 
measurements were used: arterial stiffness, cognition, body composition, bone mineral 
density, physical functioning and quality of life. The ultimate goal was to identify possible 
target groups for - preventive -  intervention in order to increase the proportion of women that 
age successfully. 
The main findings of our studies are discussed in this chapter and are placed in a broader 
context. Finally, views on further research regarding improvement of quality of life at older 
age are put forward. 
 
METHODOLOGICAL CONSIDERATIONS 
 
Study design 
 
The studies in this thesis were conducted cross-sectionally, which implies that the 
determinants and outcome were measured at the same point in time. To appreciate the 
findings some possible limitations of this approach need to be addressed. 
 
Selection bias 
 
Selection bias occurs when the relation between the determinant and the outcome is 
different for those who participated to the study and those who would be theoretically eligible 
but did not participate. Selection bias can lead to either an underestimation or an 
overestimation of an association which affects the validity of the research an which generally 
cannot be corrected for in the analyses. For example, non responders may differ from 
responders with respect to their attitude towards health, risk factor status, socio-economic 
status, and health status. Therefore it is likely that non responders are older, have higher levels 
of risk factors, and more disease compared to subjects participating in the study. Selection of 
participants in studies is very common and does generally not create validity problems. 
140 
Chapter 8 
 
However, bias due to non-response only occurs when non-response is related to the 
determinant as well as to the outcome. In order to appreciate the presence of a selection bias 
in our study, we compared the characteristics of our population with the Prospect population 
and found no significant differences other than smoking behaviour (Table 1). Therefore, we 
do not think that selection bias plays a major role. 
Table 1- Comparison of population characteristics between responders and non-responders 
 Responders Non-responders  
 
Variable mean SD mean SD p-value 
 
Age (years) 62.5 3.9 62.5 4.1 0.968 
BMI (kg/m2) 25.9 4.2 26.3 4.0 0.164 
Systolic blood pressure (mmHg) 137 22 138 22 0.619 
Diastolic blood pressure (mmHg) 79 11 79 11 0.569 
Age at menarche (years) 13.6 1.6 13.7 1.8 0.373 
Age at menopause (years) 49.4 4.7 49.4 4.7 0.911 
      
 N % N %  
Type of menopause     0.649 
    Natural 333 83 412 82  
    Surgical 68 17 88 18  
    Unknown 0 0 1 0  
Smoking behavior     0.011 
    Current 67 17 115 23  
    Past 144 36 140 28  
    Never 190 47 246 49  
Alcohol use     0.137 
    Never 47 12 68 14  
    Yes 354 88 429 86  
Fractures before age 40 years     0.266 
    Yes 85 21 85 17  
    No 315 79 416 83  
Myocardial infarction     0.332 
    Yes 7 2 12 2  
    No 394 98 489 98  
Stroke     0.531 
    Yes 7 2 8 2  
    No 394 98 493 98  
 
Another possible selection could be that participants are selected from a range of the 
determinant distribution at which the association addressed is less clear than at other parts of 
the distribution. We sampled from a base population, i.e. the Prospect cohort, comprising 
relatively young postmenopausal women, a healthy group who showed a very low rate of 
disability. This may explain that certain associations were less pronounced than expected for 
other populations. For example, we could not observe a relation between bone mineral density 
and disability. The reason to include this age group in our studies was because little data are 
available on determinants that are associated with disability early during the aging process, 
before sarcopenia has developed.  
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Confounding 
Bias due to confounding occurs in etiologic analyses when a factor is related to both the 
determinant and the outcome and is not an intermediate in the causal pathway between 
determinant and outcome. There are several ways to deal with confounding. One of the most 
frequently applied methods is statistical adjustment by including the confounder as a covariate 
in the analyses. To be able to do so, knowledge is required on which variable might be 
confounder in the association of interest and data on the variable need to have been collected. 
When a confounder is present but not measured, adjustment is not possible and the effect 
estimate will be biased. Before each analysis, we decided based on our knowledge on disease 
mechanism which factors could be confounders, or intermediate factors in the causal relation, 
and we adjusted all analyses in the present thesis for the potential confounders, as for example 
age, blood pressure and body mass index.  
 
MAIN FINDINGS 
 
a- Post menopausal estrogen levels, SHBG and arterial 
distensibility 
 
Despite the evidence of cardioprotective effects of late menopause, explained as a 
protective effect of higher premenopausal endogenous estrogen levels 1-4, we could not 
demonstrate an association between postmenopausal circulating estrogens and arterial 
distensibility. The analysis of this association is complicated by the fact that postmenopausal 
estrogen production primarily depends on the amount of peripheral fat mass, where 
conversion from precursors to estradiol takes place. The amount of peripheral fat is reflected 
in body weight, which is a strong determinant of blood pressure and atherosclerosis as well.   
Furthermore, the population may already have been too old to display a wide enough range 
of estradiol levels, and among these women, with menopause 8 to 30 years ago, endogenous 
estradiol levels are probably far below a threshold at which any beneficial arterial effect can 
be demonstrated 5.  
The relation we observed between SHBG and arterial stiffness is interesting although not 
fully understood. SHBG levels regulate plasma free and protein-bound androgens and 
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estrogens. SHBG decreases with increasing visceral fat, triglyceride and insulin 
concentrations, and increases with higher levels of HDL cholesterol. Therefore, SHBG seems 
to be an important and reliable marker of the interrelationships between sex steroid hormones, 
obesity, and cardiovascular disease risk 6-9. Recently, SHBG has been shown to mediate extra-
cellular steroid hormone actions after binding to specific high affinity SHBG receptors 10. 
However, it is not known whether an intrinsic protective effect on the arterial wall works 
through SHBG-receptors. 
 
b- Endogenous hormone levels and cognition 
 
Our results support the hypothesis that higher postmenopausal endogenous estrogen levels 
protect against mild cognitive impairment. This effect seems independent of age at 
menopause, time since menopause or body mass index, and is stronger after adjustment for 
blood pressure. The more pronounced protective effect of estrogens on cognitive decline after 
adjustment for SHBG suggests that bio-available oestrogen level is the principal determinant 
for an effect on the brain. Although serum estradiol levels increase with BMI, higher fat mass 
or BMI were not related to cognition. This suggests a role for other sources of estradiol 
production than adipose tissue, and supports the hypothesis of local estrogen biosynthesis by 
aromatase activity in the brain11. However, studies with hormone therapy have not supported 
a protective effect of exogenous estrogens on cognitive functions 12-19. As for the 
cardiovascular effects of estrogen, the populations studied in those trials may already have 
been too old at the time of substitution, where an irreversible stadium of estrogen deficiency 
has already been reached, explaining the absence of response to exogenous estradiol. To 
check this hypothesis a trial on premenopausal or early postmenopausal women should be 
performed. 
 
c- Endogenous estrogens, body composition and bone mineral 
density 
 
A major effect of fat mass on bone mineral density at all bone sites was demonstrated 
among our participants, and detailed data were provided on the strength of the effect of 
known BMD determinants at various locations. Our findings are compatible with an effect of 
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local stimulation of appendicular lean mass and muscle strength on appendicular BMD. Skull 
BMD seems to be mainly influenced by circulating estradiol and by lean mass independently 
of muscle mass. The effects of circulating estradiol levels were weaker at lower extremity and 
hip BMD sites.  
While lean mass has been shown to be the most important predictor of bone mass 
compared to fat mass in men 20, in premenarcheal girls 21 and in pre- and perimenopausal 
women 22,23, lean mass and fat mass become equally important contributors to BMD in 
postmenopausal women 24-27. Our results suggest that the importance of fat mass increases 
later in menopause. The postmenopausal changes in body composition thus have considerable 
consequences on BMD, with, apart from the mechanical load which stimulates the 
maintenance of bone mass, increased peripheral aromatization combined with a decrease in 
SHBG levels leading to higher bioactive estradiol-mediated effects. 
  
d- Menopause, body composition and physical functional status 
 
In our study population, increased fat mass was a major risk marker for decreased physical 
functional status and disability. An increase in fat mass and body weight leads to a 
compensatory increase in muscle mass and muscle strength of the legs, which, however, only 
partially prevents the decrease in physical function and the development of disability.  
The cross sectional design of the study does not allow a definitive distinction between 
cause and consequences in the described associations. Because both directions are possible, 
we did not use arrows in the algorithm shown in figure 1.  
While lean body mass is of major importance in men and premenopausal women, it 
appears that the importance of fat mass increases with age among postmenopausal women. 
Fat mass has an important effect on various outcomes: arterial stiffness with increased risk of 
cardiovascular complications, increased bone mineral density, lower physical function and 
disability, decreased health and well being. Fat mass also determines importantly levels of 
remaining endogenous oestrogens through several mechanisms of action: the load of fat mass, 
while the increased aromatisation produces higher levels of estrogens and lower levels of 
SHBG. 
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Fig. 1- Algorithm of mutual correlations between parameters which determine functional ability 
 
Disability among more obese women is partly prevented thanks to a compensatory increase 
of muscle mass en strength localised at the legs. It is probable that in this age group of healthy 
independently living women, fat mass is a more important determinant of disability, while 
sarcopenia becomes important as a determinant much later in the aging process. It is also 
known that, during the aging process, lost muscle is initially replaced by fat, but how 
precisely the age-related increase in fat mass and decrease in muscle mass interact in their 
effects and lead to disability among older people is still unanswered. It remains difficult to 
understand because of the different relationships of the various compartments of body 
composition with morbidity, disability, and health status. The factors implied in weight gain 
among middle-aged women are probably at least partly modifiable and include behaviour and 
life-style. Our observations suggest a different approach for the prevention of disability in this 
age group of postmenopausal women, than is currently considered for the oldest old (>75 
years) where the role of sarcopenia in the development of disability seems much more 
outspoken. 
The question whether overweight accelerates the process of sarcopenia  by the related 
disability cannot be answered.  
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e- Endogenous hormones, body composition and functional status 
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Fig. 2- Independent significant relations between hormone levels and physical parameters 
 
On the basis of an algorithm of the significant and independent relations found in our study 
population between body composition, muscle strength, physical performance and disability, 
we studied the associations between endogenous hormones levels and various aspects of 
physical functioning. Apart from a strong effect on bone mineral density, no effects of 
circulating estrogens were found on muscle mass, muscle strength and physical performance. 
High estrogen levels were positively related to disability, most probably because the presence 
of disability was predominantly related to overweight in this healthy population. Adrenal 
androgens (DHEA, DHEAS) and testosterone, presumably mainly produced from adrenal 
precursors, showed modest associations with bone mineral density most likely through 
aromatization to estradiol. Higher testosterone levels were related with lower physical 
performance, independently of estradiol, SHBG or insulin levels, lean mass or fat mass. As 
this was unexpected and difficult to explain, the presence of an unknown confounder in this 
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relation cannot be excluded. Insulin was positively related to lean, fat and bone mass, as 
expected for this anabolic hormone. Finally known effects of IGF-1 were confirmed with 
positive effects on leg muscle strength, physical performance and a negative effect on 
disability. 
 
f- Body composition, endogenous hormonal levels and quality of 
life 
 
Findings for the QLS-Health module and the measured physical characteristics (muscle 
strength, functional ability, bone mineral density, lean mass and fat mass) suggest an 
important role of physical well-being on the quality of life at this age. The strong inverse 
relation between disability and QLS-Health may result from limitations in participation in 
productive and recreational activities even by modest physical impairment. Of the 
components of body composition, only fat mass was related to lower QLS-Health, probably 
reflecting physical limitations due to overweight or secondary co-morbidities, impaired 
psychological functioning, and altered social functioning 28,29.  
Several hormonal factors were not found to be predictors of quality of life in this age 
group. Positive effects of estrogen therapy on quality of life at the time of menopause have 
been shown to be exclusively due to relieve of menopausal symptoms such as night sweating 
and hot flushes 30. Reported positive effects of hormone therapy on wellbeing through 
beneficial effects on bone, lipids, sexual functioning, and quality of life 29,31-33, are probably 
not measurable in the ranges of circulating endogenous hormone levels in untreated 
postmenopausal women.  
Whether a good quality of life is a consequence or a cause of an overall good physical 
functional status cannot be established because of the cross-sectional nature of this study. 
 
CLINICAL IMPLICATIONS AND FURTHER 
RESEARCH 
 
Because of our selection of participants living independently, maintaining a reasonable 
degree of physical capacity as well as a relatively good cognition, the population represents 
women that generally age successfully. To gain insight in the full spectrum of women of this 
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age group, it would be interesting to compare our results with those in a population also 
comprising institutionalised women, for example living in elderly homes. 
The critical variable for protection against cardiovascular disease as well as poor cognition 
may be lifetime duration of premenopausal estrogen exposure. Factors affecting 
premenopausal estrogen levels could be as important as those influencing estrogen levels in 
postmenopausal women. It has been suggested that estrogen treatment has its optimal 
protective effect on vascular compliance and memory when administered immediately 
following ovariectomy of pre-menopausal women or to naturally menopausal women short 
after the cessation of their menstruations 34. Consistent with the recent WHI-findings, 
estrogen given to older women would not have any beneficial effect on vascular and cognitive 
aging. Whether the critical period for the initiation of treatment is related to age, to a decrease 
of neuronal estrogen responsivity, or to the inability of the hormone to reverse neuronal loss 
and/or dysfunction which may have occurred during the estrogen deficiency state is not 
known and represents an important question for further research. Furthermore, research is 
needed to better understand the role of estrogens in cardiovascular disease prevention as well 
as in maintaining cognitive function in women and to identify ways in which we can translate 
this knowledge into clinical practice. 
Another factor of importance explaining the conflicting results concerning the effects of 
observational studies and clinical trials with estradiol therapy on cardiovascular disease and 
cognition could be the mass of fat which has major effects on endogenous hormonal levels, 
health, disability and well-being. Consistent with the higher risk of generalized 
atherosclerosis associated with obesity and considering the fact that overweight women 
generally already have higher endogenous serum levels of estrogen en lower SHBG levels, 
negative effects of hormonal therapy have been obtained among overweight women. On the 
contrary, leaner women with low estrogen levels could eventually benefit from HT. Some 
evidence for this hypothesis is given in the subgroup analysis of the WHI-study 35 but this 
should be explored further in well-powered studies. Furthermore, most women from 
observational studies probably use HT as treatment for perimenopausal complaints. No study 
has, to our knowledge, assessed the association between postmenopausal complaints and 
disease risk, which could represent a potential confounder, a modifyer of HT effect, or an 
indicator of susceptibility to effects of exogenous estrogens 36. When studying those relations, 
consideration of the time since menopause, the presence of postmenopausal complaints, and 
the BMI of individuals should be taken into account.  
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The question whether overweight accelerates the process of sarcopenia by the related 
disability cannot be answered in our population. Therefore, an intervention study with for 
example a training/exercise program and with quality of life as outcome measure should be 
performed.  
 
In conclusion, hormone therapy could be of benefit for women with low endogenous serum 
estradiol levels, before major vascular and brain damage due to low estrogen exposition have 
occurred. Accordingly, thin women with a low serum estradiol level are better candidates for 
estrogen therapy for osteoporosis prevention 37. Further research should take this into account.  
Although estrogens have been proven useful in the prevention and treatment of 
osteoporosis, and with the increased risk for breast cancer 38, hormonal substitution in a state 
of obvious atherosclerosis has been proved ineffective 39, and even associated with increased 
risk of major coronary events 40,41. Together with the shown increased risk of endometrial 
cancer with postmenopausal estrogen use 42, the preventive use of estrogen is not indicated to 
limit the aging process. Further research on selective estrogen receptor modulator (SERM) 
drugs could be a serious alternative in the future 43. Tamoxifen has been proven to be 
protective against bone loss, but had similar side effects as estrogens on the uterus. The non-
steroidal benzothiophene derivative raloxifene, is the best SERM available thus far. It does 
not increase the incidence of endometrial cancer, and like tamoxifen, it has the potential to 
prevent breast cancer, but has a better profile in its actions on bone (for example, it reduces 
the vertebral fracture rate more effectively than tamoxifen) 44,45. Unlike estrogen, it decreases 
blood triglicerides as well as cholesterol. This should be confirmed in large population-based 
studies, before preventive measures can be taken. 
An optimal individual management for every woman should be discussed with her 
caregiver. This should take into account the medical and family history as well as 
symptomatology, and the associated higher breast cancer risk. It can be uniformly 
recommended, however, that menopausal women should maintain appropriate nutrition, 
weight reduction, and exercise along with moderation in alcohol and caffeine intake and 
cessation of smoking. Data in early postmenopausal women show that exercise compensates 
at least partially for the negative effects of estrogen deficiency on bone loss, coronary heart 
disease, diabetes, and quality of life. A good physical activity, as walking more than 3 hours 
per week has been shown to be as effective as vigorous exercise to induce substantial 
reductions in the incidence of coronary events among women 46. 
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Summary/Samenvatting
Summary 
 
 
The work presented in this thesis aims to gain further insight into the associations between 
endogenous estrogens and arterial stiffness (proxy of cardiovascular disease risk), cognition, 
bone mineral density, body composition, physical functions and quality of life. This to get 
answers about successful aging and to assess the need of hormonal substitution therapy or 
other intervention susceptible to ameliorate the quality of life of women at older age. 
 
Chapter 1.  
The purpose of the thesis is introduced in light of the growth of the elderly population and 
the need for a successful aging, in the light of actual knowledge about hormonal and body 
composition changes after menopause (bone mass, fat mass), and of relations with 
cardiovascular disease, cognition, and osteoporosis. 
 
Chapter 2. 
 (Chapter 2.1). Among about 400 healthy postmenopausal women, aged 50-74 years, 
sampled from the general population, we cross-sectionally investigated the degree and potential 
cardiovascular determinants of arterial stiffness, assessed by aortic pulse wave velocity (PWV) 
measured using applanation tonometry. We found that PWV increased significantly with age, 
mean arterial pressure, pulse pressure, heart rate, and pack-years of cigarette smoking. Height 
and HDL cholesterol were found to be related with lower PWV. We also related arterial 
stiffness to absolute 10-12-year risks of stroke, coronary heart disease and death, as estimated 
by available risk functions. PWV is shown to be clear marker of an increased absolute risk of 
stroke, coronary heart disease, and death within 10-12 years 
 
 (Chapter 2.2). 
We investigated whether postmenopausal levels of sex hormones, sex hormone-binding 
globulin, and a number of other hormones which could be implicated in the aging process - 
cortisol, androstenedione, DHEA and DHEAS, Insulin-like Growth Factor (IGF-1), its 
binding proteins (IGFBP –1 and –3) and insulin - are associated with arterial stiffness among 
our healthy population of 8 to 30 years postmenopausal women. None of the other circulating 
hormone levels measured was associated to pulse wave velocity. 
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Chapter 3. 
In the same population, we cross-sectionally investigated whether levels of endogenous 
hormones, in particular circulating oestrogens and SHBG, are associated with cognition 
assessed using the mini-mental state examination questionnaire (MMSE). Our results support 
the hypothesis that higher postmenopausal endogenous estrogen levels may protect against 
cognitive impairment. This effect seems independent of age at menopause, time since 
menopause or body mass index, and stronger after adjustment for blood pressure. The 
protective effect of estrogens on cognitive decline was more pronounced after adjustment for 
SHBG, suggesting that the bio-available oestrogen level is the principal determinant for an 
effect on the brain. Serum estradiol levels increased with BMI and frequency of impairment 
in cognitive functions decreased with higher serum estradiol levels, but higher fat mass or 
BMI was not related to cognition. This suggests the importance of other sources of estradiol 
production than adipose tissue in postmenopausal women. 
 
Chapter 4. 
We investigated the variations of effects on bone mineral density at various sites of the 
following determinants: fat mass, lean mass, appendicular lean mass and muscle strength, and 
endogenous hormones. We compared the strength of effects of various determinants using 
standardised β of linear regression. Our results support an important effect of postmenopausal 
changes in body composition on BMD determinants. A major role of fat mass on bone 
mineral density at all bone sites was shown among our participants, and a detailed insight is 
given about the strength of the effect of known BMD determinants at various locations. This 
study supports a local stimulation of appendicular lean mass and muscle strength on 
appendicular BMD. Skull BMD seems to be mainly influenced by circulating estradiol and by 
lean mass independently of muscle mass. The effects of circulating estradiol levels were 
weaker at lower extremity and hip BMD sites.  
 
Chapter 5. 
We cross-sectionally investigated the relative role of fat mass, lean mass, and muscle 
strength in the development of disability in this group of healthy postmenopausal women 
younger than 75 years. Our results support the role of fat mass as the primary risk marker for 
disability, which might later accelerate by the age-related decrease in lean mass and the 
157 
Summary 
 
development of sarcopenia after the age of 75 years.  An increase in fat mass and body weight 
leads to a compensatory increase in the muscle mass and muscle strength of the legs, which, 
however, only partially prevents the decrease in physical function and the development of 
disability. 
 
Chapter 6. 
We investigated whether serum levels of circulating hormones, in particular estrogen 
concentrations, are associated with functional ability estimated by measuring muscle strength 
(grip and leg extension), physical performance, and by assessing the number of problems in 
activities of daily living (impaired ADL or disability) in the same healthy postmenopausal 
women population. We present an algorithm of the significant and independent relations 
found in our study population between body composition, muscle strength, physical 
performance and disability. On this basis, we studied the associations between measured 
endogenous hormones levels and the assessed various components of physical function. Aside 
from their strong effect on bone mineral density, no estrogen effects were found on muscle 
mass, muscle strength and physical performance. High estrogen levels were positively related 
to disability, most probably because the presence of disability was predominantly related to 
overweight in this healthy population. Hormone levels of adrenal androgens (DHEA, 
DHEAS) and testosterone, presumably mainly produced from adrenal precursors, 
demonstrated small effects on bone mineral density most likely through aromatization to 
estradiol. Still unexplained, higher testosterone levels were related with lower physical 
performance, independently of estradiol, SHBG or insulin levels, lean mass or fat mass. The 
presence of an unknown confounder in this relation can not be excluded. Insulin was 
positively related to lean, fat and bone mass, as expected for this anabolic hormone. Finally 
known effects of IGF-1 were confirmed with positive effects on leg muscle strength, physical 
performance and negative effect on disability. 
 
Chapter 7. 
We investigated whether body composition, functional status and serum hormone levels 
were associated with quality of life assessed using the questionnaire on life satisfaction 
(QLS), with two modules directed at general factors (QLS-General) and health factors (QLS-
Health) in our healthy postmenopausal women population. 
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Both QLS modules did not decrease with age, which gives a hopeful perspective and 
motivates efforts to improve quality of life at older age. The most important and specific 
determinant for psychological well being was having a partner. Higher physical performance 
and higher educational level of participants’ partners were significantly related to higher well 
being, while smoking and the presence of co-morbidities were significantly associated with a 
lower well being. Physical and psychological well being are strongly associated in this 
population, while increasing fat mass was related to decreased well being. 
No consistent relation was found between serum levels of hormones measured and both 
QLS modules, suggesting that in elderly and late postmenopausal women hormonal factors do 
not predict quality of life. 
 
Chapter 8. 
Our results are briefly summarized and some methodological questions are discussed. The 
clinical relevance of the studies presented in this thesis is discussed and hypotheses on the 
physiopathology of estrogens effects on the different determinants studied are addressed in 
the light of our findings. Finally, some ideas for further research are given. 
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Samenvatting 
 
Met het werk gepresenteerd in dit proefschrift is getracht meer inzicht te verkrijgen in de 
relatie tussen endogene circulerende oestrogenen en de volgende aspecten van de 
veroudering: vaatstijfheid (als maat van cardiovasculair risico), cognitie, bot massa, de 
lichaamssamenstelling, lichamelijke functies en de kwaliteit van het leven. Dit op zoek naar 
antwoorden omtrent succesvolle veroudering en om het nut van en behoefte aan hormonale 
substitutie therapie of eventuele andere interventies te kunnen inschatten ter verbetering van 
de kwaliteit van leven bij oudere vrouwen.  
 
Hoofdstuk 1.  
Het belang van succesvolle veroudering groeit met de toename van het aantal ouderen. Het 
doel van het proefschrift is geïntroduceerd in het licht van de actuele kennis over de 
verandering in hormonale- en lichaamssamenstelling na de menopauze (bot massa en vet 
massa) en over relaties met cardiovasculaire ziekte, cognitie en osteoporose.  
 
Hoofdstuk 2. 
(Hoofdstuk 2.1). Bij ongeveer 400 gezonde postmenopauzale vrouwen van 50 tot 74 jarige 
leeftijd, een steekproef van de algemene populatie, werd de graad en potentiële waarde van 
vaatstijfheid als determinant van het cardiovasculaire risico onderzocht, geschat middels aorta 
pulse wave velocity (PWV) meting. Vaatstijfheid nam significant toe met leeftijd, gemiddelde 
arteriële bloeddruk, pols druk, hart frequentie en het roken van sigaret uitgedrukt in “pack-
year”. Lengte en HDL cholesterol waren geassocieerd met een lagere vaatstijfheid. Onze 
resultaten tonen aan dat PWV een duidelijke marker is van een toegenomen absoluut risico 
voor beroerte, coronaire hart ziekte, en dood binnen 10-12 jaar.  
 (Hoofdstuk 2.2). 
Vervolgens werden de relaties onderzocht tussen vaatstijfheid en de postmenopauzale 
circulerende geslachtshormoon concentraties, sex hormoon bindend globuline en een aantal 
andere hormonen die mogelijk betrokken zijn in het verouderingsproces - cortisol, 
androsteendion, DHEA , DHEAS, Insulin-like Growth Factor1(IGF-1), zijn bindende 
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proteïnen (IGFBP –1 en –3) en insuline. Er werd geen relatie gevonden tussen circulerende 
hormoon concentraties en de vaatstijfheid in onze gezonde bevolking van 8 tot 30 jaar 
postmenopauzale vrouwen. 
 
Hoofdstuk 3. 
In dezelfde groep werd cross-sectioneel onderzocht of de endogene serum hormoon 
concentraties, in het bijzonder circulerende oestrogenen en SHBG, geassocieerd waren met 
cognitie gemeten met de Mini-Mental State Examination vragenlijst (MMSE). Onze 
resultaten steunen de hypothese, dat een hogere serum oestrogeen concentratie 
postmenopauzale vrouwen kan beschermen tegen cognitieve achteruitgang. Dit effect was 
onafhankelijk van menopauzeleeftijd, tijd sinds menopauze en body mass index, en was 
sterker na correctie voor de bloeddruk. Het beschermende effect van oestrogenen was meer 
uitgesproken na correctie voor SHBG, wat kan impliceren dat het biologische beschikbare 
oestrogeen gehalte de belangrijkste determinant is voor een effect op de hersenen. Het serum 
oestradiol gehalte steeg met toenemende BMI en de frequentie van cognitieve achteruitgang 
daalde bij hogere serum oestradiol concentraties, maar hogere vet massa en body mass index 
waren niet geassocieerd met cognitie. Dit suggereert de aanwezigheid en het belang van 
andere bronnen van oestradiol productie dan vetweefsel in postmenopauzale vrouwen. 
 
Hoofdstuk 4. 
Op verschillende bot locaties werden de effecten op bot minerale dichtheid (BMD) van de 
volgende determinanten onderzocht: vet massa, “spier”massa (lean mass), appendiculaire 
“spier”massa, spierkracht, en endogene hormoon concentraties. De effectsterkte van de 
diverse determinanten werd vergeleken door middel van de gestandaardiseerd β met lineaire 
regressie berekeningen. Onze resultaten ondersteunen een belangrijke invloed van de 
postmenopauzale veranderingen in lichaamssamenstelling op de determinanten van BMD. 
Een belangrijke rol van vet massa op BMD werd bij alle botlocaties aangetoond en een 
gedetailleerd inzicht over de effectsterkte van bekende determinanten van BMD per botlocatie 
werd verkregen. Deze studie toont een lokale stimulatie van appendiculaire spier massa en 
spierkracht op de appendiculaire BMD aan. Schedel BMD lijkt hoofdzakelijk beïnvloed te 
worden door het circulerend oestradiol en door de “spier”massa. Effecten van het circulerende 
oestradiol gehalte waren zwakker bij de benen en heup BMD.  
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Hoofdstuk 5. 
De relatieve rol van vetmassa, “spier”massa, en spierkracht bij de ontwikkeling van 
functionele gebreken werd cross-sectioneel onderzocht in deze groep van gezonde 
postmenopauzale vrouwen. Onze resultaten suggereren de rol van vet massa als primaire 
risico factor voor functionele gebreken, die later door de leeftijdsafhankelijke daling van 
“spier”massa, de ontwikkeling van sarcopenie boven de leeftijd van 75 jaar zouden kunnen 
versnellen. Een toename van vet massa en lichaamsgewicht leidt tot een compensatoire 
toename van de “spier”massa en de spiersterkte van de benen, die de afname van fysieke 
functie en de ontwikkeling van functionele gebreken slechts gedeeltelijk tegen gaat. 
 
Hoofdstuk 6. 
De relatie tussen circulerende hormoon concentraties - met name oestrogeenconcentraties - 
en de functionele capaciteit werd onderzocht. Functionele capaciteit werd geschat door 
middel van spierkracht, meting van fysieke prestaties en het aantal problemen in activiteiten 
van het dagelijks leven (verminderde ADL of functionele gebreken) in dezelfde groep 
gezonde postmenopauzale vrouwen. Een algoritme werd samengesteld met de significante en 
onafhankelijke relaties tussen lichaamssamenstelling, spierkracht, fysieke prestaties en 
functionele gebreken. Op deze basis werden de relaties onderzocht tussen de gemeten 
endogene hormoon concentraties en de diverse componenten van de lichamelijke functies. 
Afgezien van hun welbekende effect op de bot minerale dichtheid, werden geen effecten van 
oestrogenen aangetoond op spiermassa, spierkracht en fysieke prestaties. Hogere serum 
oestrogeen concentraties waren geassocieerd met toegenomen functionele gebreken, meest 
waarschijnlijk omdat de aanwezigheid van functionele gebreken hoofdzakelijk geassocieerd 
was met overgewicht in deze gezonde groep. Serum concentraties van bijnierandrogenen 
(DHEA, DHEAS) en testosteron, toonden kleine effecten op de bot minerale dichtheid, 
waarschijnlijk via aromatisatie van oestradiol. Een onverklaarde omgekeerde relatie werd 
gevonden tussen het testosteron gehalte en fysieke prestaties, een effect dat onafhankelijk was 
van oestradiol, SHBG of insuline gehalte, “spier”massa of vetmassa. De aanwezigheid van 
een nog onbekende confounder in deze relatie is niet uitgesloten. Insuline werd positief 
geassocieerd met “spier”-, vet- en botmassa, zoals verwacht voor dit anabole hormoon. Tot 
slot werden de bekende effecten van IGF-1 bevestigd met positieve effecten op spierkracht, 
fysieke prestaties en een negatief effect op functionele gebreken. 
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Hoofdstuk 7. 
Vervolgens werden in onze populatie van gezonde postmenopauzale vrouwen, de relaties 
onderzocht tussen lichaamssamenstelling, functionele status, circulerende hormoon 
concentraties en de kwaliteit van leven, beoordeeld door middel van een vragenlijst over 
levenstevredenheid (QLS), met twee modules: het QLS-Algemeen en het QLS-Gezondheid.  
Beide QLS modules daalden niet met leeftijd, wat een hoopvol perspectief biedt en verdere 
inspanningen ter verbetering van de kwaliteit van leven op oudere leeftijd stimuleert. De 
belangrijkste determinant voor psychologisch welzijn was het hebben van een partner. 
Grotere fysieke prestaties en een hoger onderwijsniveau van de partners van de deelnemers 
waren significant gerelateerd met een beter algemeen welzijn, terwijl roken en de 
aanwezigheid van co-morbiditeit significant geassocieerd waren met een lager algemeen 
welzijn. Fysiek en psychologisch welzijn waren sterk geassocieerd en een grotere vetmassa 
was geassocieerd met een verminderd welzijn. 
Er werden geen relaties gevonden tussen de gemeten serum hormoon concentraties en 
beide QLS modules. Dit suggereert dat bij oudere postmenopauzale vrouwen, hormonale 
factoren de kwaliteit van leven niet beïnvloeden. 
 
Hoofdstuk 8. 
Onze resultaten worden kort samengevat en enkele methodologische vragen worden 
besproken. De klinische relevantie van de studies gepresenteerd in dit proefschrift worden 
besproken en enkele pathofysiologische hypothesen omtrent de effecten van oestrogenen op 
de verschillende bestudeerde determinanten worden gepresenteerd in het licht van onze 
bevindingen. Tot slot worden ideeën voor toekomstige onderzoek gegeven. 
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